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7-O-methylflavonolignans from milk thistle were synthesized by first isolating the 
seven primary components of silymarin and individually methylating them. Optimization 
of conditions allowed for each of these seven compounds to be selectively methylated at 
the phenol in the 7-position in the presence of each metabolite's 4-5 other alcoholic 
positions without the use of protecting groups. These site-selectively methylated 
compounds were then evaluated for their cytotoxic and antiviral actions in the hepatoma 
cell line HuH7; in all cases the monomethylated analogues were more cytotoxic than the 
parent compounds. Moreover, parent compounds that were relatively non-toxic and 
inactive or weak inhibitors of hepatitis C virus infection had enhanced toxicity and anti-
HCV activity upon 7-O-methylation. Also, the compounds were tested for inhibition of 
major drug metabolizing enzymes in pooled human liver and intestinal microsomes. 
Methylation of flavonolignans differentially modified inhibitory potency, with 
compounds demonstrating both increased and decreased potency depending upon the 
compound tested and the drug metabolizing enzyme system investigated. In total, these 
data indicated that monomethylation modulates the cytotoxic, antiviral, and drug 
interaction potential of silymarin flavonolignans.  
A biomimetic synthesis of flavonolignans was also accomplished. Coniferyl 
alcohol was oxidized using silver oxide  in the presence of taxifolin to form four of the 
major components of silymarin, silibinin (silybin A and silybin B), and isosilibinin 
(isosilybin A and isosilybin B). The mechanism of this transformation was probed and it 
appears to undergo two sequential single electron oxidations with coupling of coniferyl 
alcohol to taxifolin between the two oxidations. Synthetic flavolignans were confirmed to 
be identical to natural compounds by NMR, HPLC, UPLC and HRMS. This results in a 
good yield of some of the minor natural compounds, such as isosilybin B.  Moreover, it 
provides a means to generate structural analogues.   
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CHAPTER I 
SEMISYNTHESIS, CYTOTOXICITY, ANTIVIRAL ACTIVITY, AND DRUG 
INTERACTION LIABILITY OF 7-O-METHYLATED ANALOGUES OF 
FLAVONOLIGNANS FROM MILK THISTLE 
 
     This chapter has been accepted by the Journal, Bioorganic and Medicinal Chemistry. 
 
 
1.1. Introduction 
1.1.1.  Milk thistle: flavonolignans nomenclature and stereochemistry  
Milk thistle (Silybum marianum) (L.) Gaertner (Asteraceae) is a biennial plant native to 
Mediterranean regions and has been used for several liver diseases. Milk thisle derives its 
name from the milky veins leaves.1,2 This plant can rich in height of 2-3 meters and has 
purple flowers with green spiky leaves (Fig. 1.1), in 1970s a new white-flowered variety 
was found.1,3 The flowers of milk thistle hold seeds that contain a primary active extract 
compound called silymarin which was isolated in 1968 by Wagner.4, 5 
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Figure1.1. Milk thistle flower. These photos were taken at UNCG, Dr. Oberlies lab, 
3/10/2013 (Hanan Althagafy) 
 
 
Silymarin was considered as a one compound with the structure of 7-chromanol-
3-methyl-taxifolin, but separation method was shown that silymarin consists of a mixture 
of seven diastereoisomers flavonolignans, include: silybin A (1), silybin B (2), isosilybin 
A (3), isosilybin B (4), silychristin (5), isosilychristin (6), and silydianin (7; Fig. 1.2).6-10  
The structures and stereochemistry of flavonolignans were extensively studied 
between 1960 and the mid-1980s by Hänsel and Wagner independently.11-18 Silybin A 
and B were initially isolated and characterized as a mixture.  Besides silybin, two other 
compounds silychristin and silydianin were isolated.19,12  However, in 1974 Wagner 
reported other constituent, isosilibinin also as one compound.14 Silibinin and isosilibinin 
structures were determined based on degradative work and the synthesis and  
characterization of the dehydrosilybinin pentamethyl ether.12,13,15  
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In 1979, Arnone  et al.,14 determined the structure of the two individual 
diastereoisomers of silybinin and isosilibinin based on their comparison study of 
biomimetic synthesis products.  
Separation of both diastereoisomers and the absolute configuration of silybin A, B 
and isosilybin A, B were complicated in 2003 as: silybin A, 2R, 3R, 7′′R, 8′′R; silybin B, 
2R, 3R, 7′′S, 8′′S; isosilybin A, 2R, 3R, 7′′R, 8′′R; and isosilybin B, 2R, 3R, 7′′S, 8′′S, 
using 2D NMR, X-ray crystallographic analysis and CD.20,21 
 
 
 
Figure 1.2. Structures for the seven major flavonolignans from silymarin 
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1.1.2. Hepatoprotactive activity of flavonolignans 
Initially, flavonolignans were isolated and used in clinical research as a 
hepatoprotective agents;22-24 hepatitis25, cirrhosis, alcoholic liver diseases26, poisoning by 
phalloidin,27,28 chemicals29 and toxin drug-induced.30,31 In animal experiments, silymarin 
and silibinin have been shown to prevent the cirrhotic changes in rat against 
hepatotoxicity induced by some chemical such as carbon tetrachloride and against 
amanita phalloides.32-34 Silymarin regulates inflammatory mediators such an 
interleukins,35 tumor necrosis factor (TNF)36 and inhibits NF-κB activation.37,38   
Also silymarin components modulate protein kinases and suppress cellular 
proliferation.39,40 The influence of the flavonolignane on the rate of RNA synthesis was 
studied in rat livers. ~60% increase in nuclear RNA synthesis was observed.41,42 
Experimental studies showed that silymarin can promote DNA polymerase and enhance 
hepatocyte regeneration.42,43  
Studies showed that silymarin increase the anti-oxidants levels; stabilize the 
plasma membrane by reducing lipid peroxidation and free radical production.44-46 The 
effect of silymarin on phospholipid in rat liver and brain microsomal membranes was 
studied. Resultes showed that silymarin effective the lipoxygenase and cyclooxygenase 
pathways.47,48 Therefore, flavonolignans may be useful to inhibit the fatty acid 
peroxidation and control the prostaglandin formation.49,50 
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1.1.3 Anti-cancer activity of flavonolignans  
Flavonolignans have been demonstrated to have strong anti-tumor, 
chemoprevention and anti-proliferative activities.51-54 More recent studies have shown 
that flavonolignans 1-4 are selective inhibitors against large types of cancer cell lines. 55 
There are several studies in an animal and cell culture that show  selective inhibitor of 
silibinin and isosilibinin against large types of cancer cell lines such as,  SHP-77 and 
A549 lung cancer cells,54,56,57 K562 human leukemia,58 renal cell carcinoma (RCC) 
metastasis,59,60 human breast cancer MCF-7 cells,61,62 colorectal cancer LoVo cells,63,64 
colon carcinoma HT-29 cells65  and human prostate carcinoma PC-3.66,67 
 In a xenograft mice model using a DU145 human prostate cancer cells, dietary 
silibinin significantly reduced the xenograft tumor growth.68,69 In addition silibinin has 
shown strong anticancer efficacy against both androgen-dependent and androgen-
independent prostate cancer cells.70,71 Silymarin and silybin were shown to suppress the 
activity of the DNA topoisomerase II alpha gene promoter in DU145 cells.72  
Silibinin strongly inhibit cell proliferation at the G1-phase of the cell cycle and 
inhibit angiogenesis, and enhanced apoptosis in the prostate tumor cells.39,73 Molecular 
studies showed that silymarin caused p21/Cip 1, p27/Kip1, G1 and G2-M cell cycle arrest 
associated with decrease in dependent kinase CDK4, CDK6 and CDK2 protein levels.74-
76   Animal study showed that silybin also increased activated caspase-3- positive cells  
and decreased vascular endothelial growth factor (VEGF) expression in tumors.73,77   At 
low doses silymarin was shown to inhibit ERK1/2 activation, and at higher doses 
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silymarin stimulated JNK activation in A431 cells. 39,59,78 Silibinin has shown synergic 
anti-cancer activity in prostate cancer models when combined with doxorubicin37. 
Moreover, isosilybin B, which is no more than 5% of silymarin, has been shown to have 
significant antiproliferative activity against human prostate cell lines (PCA DU145, PCA 
LNCaP and 22Rv1).72,79,80  
1.1.4 Metabolism and pharmacokinetic of flavonolignans 
Metabolism of silymarin components are started early and referred to study on  
silibinin.81-83 Silibinin has been shown to undergo sulfates and glucuronides conjugation 
(phase II) reactions and are excreted into bile and urine.81,84-86 The hydroxylation 
(CYP2E1), oxidation (CYP3A4) and demethylation metabolism (phase I) of silibinin by 
CYP450 enzymes have been also observed (Fig. 1.3).87,88  
Silibinin in vitro and in vivo has been shown prominent inhibition and alter the 
activities of a variety of cytochrome P450 isoenzymes, such as; CYP3A488 and CYP2C9 
isoforms89,90 (IC50 < 50 mu M), UDP glucuronosyltransferase isoform1A1 (UGT1A1) 
and P-glycoprotein (P-gp)mediated efflux transporters.91-93 A weak interaction with 
human microsomal CYP2E1, 2A6, 2B6, 2C19, and 2D6 (IC50 > 250 mμ M) was found; a 
moderate inhibition was observed for CYP1A2 and 2C8.94  
It is important to mention that the flavonolignans cytochrome P450 interaction is 
dose dependent.  This modulation may interact with metabolism of therapeutic drugs or 
reduce the activity of carcinogenic compounds.  
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Silibinin absorption and bioavailability are low due to extensive multiple 
conjugation reactions.10,81,86 In general hydroxyl of phenolic group at C-7 and C-4″ are 
the major sites for glucuronidation.  Studies in the glucuronidation process showed that 
these are a significant chemoselective. The glucuronidation of silybin B was more 
efficient rate than silybin A. Glucuronidation at the C-4″ position was much preferred in 
silybin B. However, in case of silybin A glucuronidation was similar at the C-7 and C-
4″.81,95 In sulfation reactions there is a similarity in reaction rate in case of silybin A and 
silybin B.81 The conjugation metabolites such as mono-methylated at C-7 and di-
methylated at C-7 and C-4″ have been shown to have a biological activity.66,96 
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Figure 1.3  Oxidative, demethylenation and subsequent glucuronidation are the major 
flavonolignans metabolic products 
 
 
1.1.5  History of flavonolignans derivatives  
Several analogues of silibinin were synthesized from beginning of 1970s with 
better bioavailability, solubility and activities. Synthesis of the 3, 4″-O-bis-hemisuccinate 
silybin, was the first example of a water-soluble analogue silybin.97,98 Glycosides 
semisynthetic derivatives also enhanced water-soluble and the antioxidant property.10,99 
Silibinin in a complex with phosphatidylcholine has been developed to increase its  
bioavailability and absorption.100-102 In animal models phosphatidylcholine shows greater 
oral bioavailability as indicated by higher plasma silybin levels and greater activity 
compared with with pure silybin. Complexes of flavanolignans (silybin, silidianin, and 
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silicristin) with phospholipids are prepared to enhance absorption in the gastrointestinal 
tract. This flavonolignans-lipophilic complex was used orally administered to carbon 
tetrachloride-treated rats to inhibit the liver toxicity.98  
Silybin esterification with long-chain fatty acids were tested as anti-influenza 
virus activities and for their antioxidant (inhibition of lipid peroxidation and it found that 
the activity improved with increasing length of the acyl moiety.103,104 
It also found that carboxylic acid derivatives of silybin and 2,3-dehydrosilybin improved 
the antioxidant effectiveness.105,106 O-alkyl derivatives (methyl and benzyl) of silibinin 
and 2,3-dehydrosilibinin enhanced the cytotoxicity in multidrug resistant cell lines.96 The 
7-O-monomethyl and 7, 4″-O-dimethyl analogues were shown to have enhanced 
cytotoxicity, antiviral activity (up to 6-fold increased potency) compared to the parent 
compound (Figure 1.4). 66 Gažák and his co-workers synthesized O-galloylsilybin for 
pure silybin A and silybin B and for the mixture (silibinin) and the derivitives showed 
good antiangiogenic activity 108 
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(1) R1, R2, R3, R4 = H (IC50 = 60.5 ± 4.3) 
(2) R1, R2, R3 = CH3; R
4 = H (IC50 = 36.3 ± 3.7) 
(3)  R1 = CH3, R
2, R3, R4 = H (IC50 = 16.9 ± 3.6) 
(4) R1, R3 = CH3; R
2, R4 = H(IC50 = 8.1 ± 3.5)  
(5) R1, R2, R3, R4 = CH3 (IC50 = 14.4 ± 4.4)  
(6) R1, R3, R4 = CH3, R
2 = H (IC50 = 21.9 ± 4.1) 
 
Figure 1.4 Silybin B and the methylated analogues 2-6 and IC50 values
66 
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1.1.6 Aim of the work 
The goal of the present study was to expand upon that initial SAR by selectively 
synthesizing 7-O-methyl analogues of the seven major flavonolignans. However, rather 
than relying upon protecting groups, which require two additional synthetic steps for 
installation and removal, it was hypothesized that the inherent reactivity of the molecule 
could be harnessed to guide the selectivity. By judicious choice of reaction conditions, a 
single position, the C-7-phenol, was methylated selectively in the presence of multiple 
centers with similar reactivity, including two or three other phenolic positions, a similarly 
acidic secondary alcohol, and a primary alcohol. This chemoselectivity was comparable 
for all seven flavonolignans, which enabled the site-specific analysis of the importance of 
the methylated phenol for each compounds activity in a suite of bioassays that probed 
cytotoxicity, anti-hepatitis C virus (HCV) activity, and inhibition of prominent drug 
metabolizing enzymes.  
1.2 Result and Discussion 
1.2.1 Chemistry 
The synthesis of 7-O-methyl analogues of the natural flavonolignans was 
challenging due to the possibility of alkylation at more than one hydroxyl group. 
Therefore, a variety of bases [Cs2CO3, K2CO3, and Diazabicycloundecene (DBU)], 
electrophilic methylating agents (dimethyl carbonate, methyl iodide), solvents (acetone, 
THF, acetonitrile), temperatures (rt to 75 °C under standard heating or up to 130 °C  
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using microwave heating), and times (2 h to 2 days) were examined, all with the goal of 
minimizing the formation of polymethylated side products. Selective monomethylation of 
the phenolic group at C-7 was possible for all seven major flavonolignans over a 
temperature range of 30–60 °C using methyl iodide in dry acetone in the presence of 
K2CO3. The 7-position was the most reactive for methylation, presumably due to both 
acidity, being an arylogous carboxylic acid, and steric accessibility. While the yields 
were moderate to low, ranging from approximately 20 to 40%, the reaction conditions 
were optimized for selective monomethylation rather than yield.  
 1.2.2  Purification  
Published methods were utilized to isolate the individual flavonolignans as 
starting materials for the methylation reactions.108 To purify the reaction mixtures, two 
different reverse-phase columns [ODS-A C18 (5 µm; 250 × 20 mm) and PFP (5 µm; 250 
× 21 mm)] were examined. ODS-A C18 gave a good result in separation of 
disterioesomers and PFP gave a good result in separation of other anpurities that not 
separated in C18 column. PFP gave the best results according to peak symmetry and 
resolution when using acetonitrile as the organic modifier (data not shown). Accordingly, 
each 7-O-methylated flavonolignan analogue was purified until >98% pure, as measured 
by analytical HPLC (see the experiment section). 7-O-methylsilybin A (2) and 7-O-
methylisosilybin A (6) were purified using a gradient of 30:70 to 50:50 CH3CN:H2O 
(0.1% formic acid) over 30 min. 7-O-methylsilybin B (4) was purified using a gradient of 
20:80 to 40:60 CH3CN:H2O (0.1 % formic acid) over 30 min. 7-O-methylisosilybin B (8) 
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was purified using 20:80 to 60:40 CH3CN:H2O (0.1 % formic acid) over 40 min. 7-O-
methylsilychristin (10) and 7-O-methylsilydianin  (12) were purified using a gradient of 
20:80 to 36:64 CH3CN:H2O (0.1% formic acid) over 24 min. 7-O-methylisosilychristin 
(14) was purified using a gradient of 15:80 to 36:64 CH3CN:H2O (0.1 % formic acid) 
over 26 min.  
1.2.3 Structure determination 
Structures of the 7-O-methylated analogues were determined using a suite of NMR 
spectroscopy and mass spectrometry experiments (see Tables 1, 2 and 3). Using the data 
for 7-O-methylsilybin A (2) as a representative example, two methoxy singlets were 
apparent at δH 3.78 (3H) and 3.77 (3H), due to the introduced methoxy group at C-7 and 
the natural one at C-3″, respectively. In contrast, the parent flavonolignan silybin A (1) 
displayed a sharp singlet at δH 10.86 for the C-7 phenolic proton signal. Further evidence 
for the methoxy group on C-7 in analogue 2 was observed in the meta-coupled protons at 
H-6 and H-8 (δH 6.12 and 6.10, respectively), which were shifted downfield slightly 
compared to 1 (Table 1.1 and 1.2). The 13C NMR data (Table 1.2) of each methylated 
analogue displayed 26 distinct signals, which was one more than the non-methylated 
starting materials, including resonances at δC 56.0 and 55.7 due to the two methoxy 
moieties at C-7 and C-3″, respectively; these assignments were supported by HSQC 
correlations. Moreover, data from the HMBC experiment demonstrated the connectivity 
of the methoxy moieties, where correlations were observed between the protons at δH 
3.78 to C-7 (δC 167.6) and δH 3.77 to C-3″ (δC 147.6), respectively, verifying that the  
14 
 
introduced methoxy moiety was at the C-7 position in 2. For each of the analogues, a 
similar set of NMR experiments and data, coupled with comparisons to the data for the 
natural flavonolignans, were utilized to establish that the methoxy moiety was connected 
at the 7 position in all of the analogues. Finally, HRMS data supported the introduction of 
a single methyl moiety, where the [M-H]- ion peak for all of the analogues was fourteen 
mass units greater than that of the parent flavonolignans (see experimental). 
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Table 1.1. 1H NMR data of flavonolignans (1, 3, 5, 7) and 7-O-methylflavonolignans (2, 4, 6, 8) in DMSO-d6 (500 MHz, 30 
°C) 
position 1 2 3 4 5 6 7 8 
2 5.08, d 
(11.5) 
5.14, d 
(11.5) 
5.08, d 
(11.5) 
5.14, d 
(11.5) 
5.11, d 
(10.9) 
5.16, d 
(10.9) 
5.11, d 
(11.5) 
5.16, d 
(11.5) 
3 4.63, dd 
(11.5, 6.3) 
4.69, dd 
(11.5, 6.3) 
4.61, dd 
(11.5, 6.3) 
4.67, dd 
(11.5, 6.3) 
4.60, dd 
(10.9, 6.3) 
4.66, dd 
(10.9, 6.3) 
4.61, dd 
(11.5, 5.9) 
4.67, dd 
(11.5, 6.3) 
6 5.91, d (1.7) 6.12, d (1.7) 5.91, d (2.3) 6.12, d (2.3) 5.92, d (2.3) 6.13, d (2.3) 5.92, d (2.0) 6.13, d (2.3) 
8 5.86, d (1.7) 6.10, d (1.7) 5.87, d (2.3) 6.10, d (2.3) 5.89, d (2.3) 6.12, d (2.3) 5.89, d (2.0) 6.12, d (2.3) 
2' 7.09, d (1.7) 7.10, d (1.7) 7.08, d (1.8) 7.10, d (2.3) 7.09, d (2.3) 7.11, d (2.3) 7.10, d (1.8) 7.11, d (1.7) 
5' 6.97, d (8.0) 6.98, d (8.6) 6.97, d (8.1) 6.98, d (8.0) 6.93, d (8.6) 6.94, d (8.6) 6.93, d (8.0) 6.94, d (8.0) 
6' 7.00, dd  
(8.0, 1.7) 
7.01, dd 
(8.6, 1.7) 
7.02, dd 
(8.1, 1.8) 
7.02, dd 
(8.0, 2.3) 
6.98, dd 
(8.6, 2.3) 
6.99, dd 
(8.6, 2.3) 
6.98, dd 
(8.0, 1.8) 
7.00, dd 
(8.0, 1.7) 
2'' 7.01, d (1.8) 7.03, d (1.8) 7.02, d (1.7) 7.04, d (1.7) 7.00, d (1.7) 7.00, d (1.7) 7.00, d (2.3) 7.01, d (1.8) 
chemical shifts in δ, coupling constants in Hz 
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Table 1.1. 1H NMR (continued) 
position 1 2 3 4 5 6 7 8 
5'' 6.80, d (8.6) 6.80, d (8.6) 6.79, d (8.6) 6.80, d (8.0) 6.80, d (8.6) 6.80, d (8.0) 6.80, d (8.6) 6.80, d (8.2) 
6'' 6.86, dd 
(8.6, 1.8) 
6.86, dd 
(8.6, 1.8) 
6.86, dd 
(8.6, 1.7) 
6.86, dd 
(8.0, 1.7) 
6.86, dd 
(8.6, 1.7) 
6.85, dd 
(8.0, 1.7) 
6.86, dd 
(8.6, 2.3) 
6.85, dd 
(8.2, 1.8) 
7'' 4.90, d (7.5) 4.91, d (7.5) 4.90, d (7.5) 4.91, d (7.5) 4.91, d (8.1) 4.91, d (7.5) 4.91, d (7.5) 4.92, d (7.5) 
8'' 4.17, ddd 
(7.5, 4.6, 
2.3) 
4.18, ddd 
(7.5, 4.6, 
2.3) 
4.16, ddd 
(7.5, 4.1, 
2.3) 
4.17, ddd 
(7.5, 4.6, 
2.3) 
4.16, ddd 
(8.1, 4.6, 
2.3) 
4.17, ddd 
(7.5, 4.0, 
2.3) 
4.17, ddd 
(7.5, 4.6, 
2.3) 
4.17, ddd 
(7.5, 4.6, 
1.7) 
9''a 3.53, ddd 
(10.3, 5.2, 
2.3) 
3.53, ddd 
(10.3, 5.2, 
2.3) 
3.53, ddd 
(9.8, 4.6, 
2.3) 
3.54, ddd 
(12.0, 5.2, 
2.3) 
3.53, ddd 
(12, 4.6, 
2.3) 
3.53, ddd 
(12.0, 4.6, 
2.3) 
3.54, ddd 
(11.9, 5.2, 
2.3) 
3.53, ddd 
(10, 5.2, 
1.7) 
9''b 3.33, m 3.34, m 3.33, m 3.33, m 3.33, m 3.33, m 3.33, m 3.33, m 
7-OCH3 - 3.78, s - 3.78, s - 3.79, s - 3.79, s 
chemical shifts in δ, coupling constants in Hz  
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Table 1.1. 1H NMR (continued) 
position 1 2 3 4 5 6 7 8 
3''-OCH3 3.77, s 3.77, s 3.77, s 3.77, s 3.78, s 3.77, s 3.77, s 3.77, s 
3-OH 5.83, d (6.3) 5.90, d (6.3) 5.83, d (6.3) 5.89, d (6.3) 5.83, d (6.3) 5.91, d (6.3) 5.84, d (5.9) 5.91, d (6.3) 
5-OH 11.90, s 11.86, s 11.90, s 11.87, s 11.90, s 11.87, s 11.90,  s 11.87, s 
7-OH 10.86, s - 10.86, s - 10.85, s - 10.86 s - 
4''-OH 9.18, s 9.19, s 9.17, s 9.18, s 9.15, s 9.18, s 9.16, s 9.18, s 
9''-OH 4.97, dd 
(5.7, 5.2) 
4.98, dd 
(5.7, 5.2) 
4.98, dd 
(5.7, 4.6) 
4.98, dd 
(5.7, 5.2) 
4.95, dd 
(5.7, 4.6) 
4.97, dd 
(5.7, 4.6) 
4.96, dd 
(5.5, 5.0) 
4.97, dd 
(5.2, 4.6) 
chemical shifts in δ, coupling constants in Hz 
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Table 1.2. 1H NMR data of flavonolignans (9, 11, 13) and 7-O-methylflavonolignans (10, 12, 14) in DMSO-d6 (500 MHz, 30 
°C) 
position 9 10 11 12 13 14 
2 5.02, d (11.4) 5.05, d (11.4) 5.17, d (11.9) 5.22, d (11.4) 4.86, dd (10.4) 4.91, dd (10.4) 
3 4.52, dd (11.4, 
6.4) 
4.58, dd (11.4, 
6.3) 
4.64, dd (11.9, 
6.5) 
4.67, dd (11.4, 
6.9) 
4.44, dd (10.4, 
5.4) 
4.48, dd (10.4, 5.4) 
6 5.91, d (2.0) 6.12, d (2.3) 5.93, d (1.9) 6.13, d (2.0) 5.91, d (2.5) 6.12, d (1.9) 
8 5.86, d (2.0) 6.09, d (2.3) 5.88, d (1.9) 6.11, d (2.0) 5.88, d (2.5) 6.11, d (1.9) 
2' 6.82, d    (1. 5) 6.84, d (1.2) - - 3.44, dd (4.0, 
2.0) 
3.45, dd (4.0, 2.0) 
5' - - 6.75, d (8.1) 6.74, d (8.1) 3.17, dd (8.9, 
3.0) 
3.19, dd (6.9, 3.0) 
6' 6.87, br s  6.88, br s 6.96, d (8.1) 6.97, d (8.1) 5.92, d    (8.9) 6.01, d (6.9) 
2'' 6.96, d    (2.0) 6.96, d (1.8) 6.86, d (1.5) 6.86, d (2.0) 6.75, d (2.0) 6.76, d (1.9) 
5'' 6.76, d (8.4) 6.76, d (8.1) 6.70, d (7.9) 6.69, d (8.5) 6.63, d (8.5) 6.64, d (8.4) 
chemical shifts in δ, coupling constants in Hz 
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Table 1.2. 1H NMR (continued) 
 
position 9 10 11 12 13 14 
6'' 6.80, dd (8.4, 
2.0) 
6.81, dd (8.1, 
1.8) 
6.76, dd (7.9, 
1.5) 
6.76, dd (8.5, 
2.0) 
6.55, dd (8.5, 
2.0) 
6.56, dd (8.4, 1.9) 
7'' 5.46, d (7.0) 5.46, d (6.9) 5.58, d (2.5) 5.57, d (2.5) 3.31, b s 3.31, b s 
8'' 3.47, ddd 
(12.6, 12.0, 
7.0) 
3.47, ddd 
(12.6, 12.0, 
6.9) 
3.67, m 3.67, m 2.72, b s 2.73, br s 
9''a 3.72, ddd 
(12.6, 10.9, 
5.0) 
3.72, ddd 
(12.6, 10.9, 
5.2) 
3.68, m 3.68, m 4.12, dd (8.0, 
3.0) 
4.13, dd (8.0, 3.0) 
9''b 3.63, ddd 
(12.6, 10.9, 
5.6) 
3.63, ddd 
(12.6, 10.9, 
5.7) 
3.45, m 3.44,  m 3.78, d (8.0) 3.78, d (8.0) 
chemical shifts in δ, coupling constants in Hz  
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Table 1.2. 1H NMR (continued) 
position 9 10 11 12 13 14 
7-OCH3 - 3.78, s - 3.80, s - 3.79, s 
3''-OCH3 3.76, s 3.76, s 3.70, s 3.69, s 3.73, s 3.74, s 
3-OH 5.77, d (6.4) 5.81, d (6.3) 5.76, d (6.5) 5.81, d (6.9) 6.02, d (6.3) 6.04, d (6.3) 
5-OH 11.91, s 11.87, s 11.93, s 11.90, s 11.81, s 11.77, s 
7-OH 10.84, s - 10.98, s - 10.9, s - 
4''-OH 9.03, s 9.02, s 9.00, s 8.99, s 8.79, s 8.79, s 
9''-OH 5.01, dd (5.6, 
5.0) 
5.01, dd (5.7, 
5.2) 
5.07, br dd (4.5, 
2.0) 
5.06, dd (6.5, 
4.5) 
  
3'-OH     7.19, s 7.17, s 
chemical shifts in δ, coupling constants in Hz  
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Table 1.3. 13C NMR data of flavonolignans and 7-O-methylated analogues in DMSO-d6 (125 MHz, 30 °C).  
position type 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
2 CH 82.6 82.7 82.5 82.7 82.5 82.7 82. 5 82.7 83.3 83.4 79.9 80.0 81.7 81.8 
3 CH 71.4 71.5 71.4 71.5 71.5 71.6 71.5 71.6 71.7 71.8 71.5 71.7 70.8 71.0 
4 C 197.8 198.5 197.7 198.5 197.8 198.5 197.8 198.4 197.8 198.4 198.2 198.7 196.5 197.6 
4a C 100.4 101.4 100.4 101.4 100.5 101.4 100.5 101.4 100.5 101.4 100.6 101.5 100.3 101.2 
5 C 163.3 163.0 163.3 163.0 163.3 163.0 163.3 163.0 163.3 163.0 163.4 163.1 163.4 163.0 
6 CH 96.1 95.0 96.1 94.9 96.1 95.0 96.1 95.0 96.0 94.9 96.1 95.0 96.2 95.2 
7 C 167.1 167.6 166.9 167.6 166.9 167.6 166.9 167.6 166.8 167.5 166.8 167.6 166.9 167.6 
8 CH 95.1 93.9 95.0 93.9 95.1 93.9 95.1 93.9 95.0 93.8 95.1 93.9 95.0 93.8 
8a C 162.5 162.4 162.4 162.4 162.5 162.4 162.5 162.4 162.6 162.5 162.6 162.5 162.0 162.0 
1' C 130.1 129.9 130.1 130.0 130.3 130.2 130.3 130.2 130.0 129.8 124.5 124.4 139.5 139.4 
2' CH 116.6 116.7 116.6 116.7 116.5 116.6 116.5 116.5 115.6 115.7 128.9 128.9 48.6 48.7 
3' C 143.3 143.3 143.2 143.2 142.9 142.9 142.9 142.9 146.4 146.4 141.6 141.6 96.7 96.7 
chemical shifts in δ 
 
 
22 
Table 1.3. 13C NMR (continued) 
position type 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
4' C 143.7 143.7 143.6 143.7 143.9 143.9 143.9 143.9 140.7 140.7 145.9 145.8 201.9 201.9 
5' CH 116.3 116.4 116.3 116.4 116.4 116.5 116.5 116.4 129.1 129.1 116.1 116.1 53.4 53.3 
6' CH 121.4 121.5 121.1 121.2 120.9 121.0 120.9 121.0 115.4 115.4 119.5 119.4 124.0 124.0 
1'' C 127.5 127.5 127.5 127.5 127.5 127.5 127.5 127.5 132.4 132.4 132.8 132.8 133.0 133.0 
2'' CH 111.6 111.6 111.6 111.6 111.7 111.7 111.7 111.7 110.4 110.9 110.2 110.3 112.4 112.4 
3'' C 147.6 147.6 147.6 147.6 147.6 147.6 147.6 147.6 147.5 148.1 147.5 147.5 147.1 147.2 
4'' C 147.0 147.0 147.0 147.0 147.0 147.0 147.0 147.0 147.1 147.7 146.3 146.3 145.1 145.1 
5'' CH 115.3 115.3 115.3 115.3 115.3 115.3 115.3 115.3 115.3 115.3 115.1 115.1 114.9 115.0 
6'' CH 120.5 120.6 120.5 120.5 120.5 120.5 120.5 120.4 118.7 118.7 118.5 118.6 120.3 120.3 
7'' CH 75.9 75.9 75.8 75.9 75.9 75.9 75.9 75.9 87.0 87.5 86.4 86.4 46.0 46.0 
8'' CH 78.1 78.1 78.1 78.1 78.0 78.0 78.0 78.0 53.4 53.9 52.0 51.9 44.0 44.0 
9'' CH2 60.2 60.2 60.2 60.2 60.2 60.2 60.2 60.2 63.0 63.5 63.5 63.5 72.8 72.8 
chemical shifts in δ  
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Table 1.3. 13C NMR (continued) 
position type 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
3''-OCH3 CH3 55.7 55.7 55.7 55.7 55.7 55.7 55.7 55.7 55.6 55.6 55.6 55.6 55.4 55.4 
7-OCH3 CH3 - 56.0 - 56.0 - 56.0 - 56.0  55.9 - 56.0 - 56.0 
chemical shifts in δ  
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1.3. Biological Studies  
1.3.1. Cytotoxicity and cell viability 
 In comparing the cytotoxicity profiles of 7-O-methylated analogues vs. parental 
counterparts (Table 1.4), addition of a single methyl group increased cytotoxicity against 
human hepatoma cells (Huh7.5.1). These findings were consistent with an earlier pilot 
study that examined a series of mono-, di-, tri- and tetra-methylated analogues of silybin 
B (3).66 Silychristin (9), isosilychristin (11), and silydianin (13) have been reported to be 
relatively non-toxic compared to the other silymarin flavonolignans.109 In the current 
study, marked increases in the cytotoxicity of silydianin (13), silybin A (1), and isosilybin 
A (5) were observed upon methylation (compounds 14, 2, and 6, with 13.8, 8.4, and 6.1 
fold, respectively). However, the 7-O-methylation of isosilybin B (7) did not produce a 
pronounced increase in cytotoxicity (i.e., compound 8), which was interesting given that 
7 has been shown to be the most cytotoxic of the parent flavonolignans, particularly in 
assays for prostate cancer chemoprevention.80,109-113 
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Table 1.4. Cytotoxic activity of flavonolignans and 7-O-methylated analogues against 
human hepatoma (Huh7.5.1) cells.  
Compound IC50 Values (μM) Fold Change 
a,b
Silybin A (1) 80.0  
7-O-Methylsilybin A (2) 9.5 8.4 
Silybin B (3) 68.7  
7-O-Methylsilybin B (4) 12.7 5.5 
Isosilybin A (5) 80.0  
7-O-Methylisosilybin A (6) 13.2 6.1 
Isosilybin B (7) 27.0  
7-O-Methylisosilybin B (8) 18.0 1.5 
Silychristin (9) >130  
7-O-Methylsilychristin (10) 66.4 >2 
Isosilychristin (11) >130  
7-O-Methylisosilychristin (12) 27.6 >4.7 
Silydianin (13) >130  
7-O-Methylsilydianin (14) 9.4 13.8 
Resveratrolc 10.6  
a The fold change was calculated by dividing the IC50 value for the parent 
flavonolignan by the IC50 value for the corresponding 7-O-methylated 
analogue.  
b The average fold change for all analogues was approximately 6.  
c Typical average value as a positive control for the assay.  
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1.3.1.1. Anti-viral activity 
In evaluating the anti-HCV profiles of these compounds (Fig. 1.5), some of the 
methylated flavonolignans displayed greater anti-HCV activity [i.e. 7-O-
methylsilychristin (10), 7-O-methylisosilychristin (12)] than the corresponding parent 
compounds. In particular, silychristin (9), isosilychristin (11), and silydianin (13) did not 
show appreciable antiviral activity until they were methylated (i.e., 10, 12, and 14).  
On the other hand, if parent compounds were active in blocking HCV activity, 
such as silybin A (1), silybin B (3), and isosilybin A (5), the methylated counterparts 
either retained (2) or decreased (4, 6) activity. The most toxic parent compound, 
isosilybin B (7), had a slight enhancement of both antiviral activity and cytotoxicity 
(Table 1.4) by methylation (compound 8). Thus, it appeared that HCV antiviral activity 
tracked with cytotoxicity. That is, as compounds became more toxic, the more likely 
antiviral activity was detected. However, that is not to say that antiviral activity coincided 
with cytotoxicity, as we were always able to detect anti-HCV activity that was 
independent of cytotoxicity. 
We hypothesize that flavonolignans target shared cellular functions that confer 
both cytotoxic and antiviral activities. Huh7.5.1 cells were infected with JFH-1 at a 
multiplicity of infection of 0.05. Virus inoculum was removed after 5 h and compounds 
were added. Cultures were incubated for 72 h before protein lysates were analyzed for 
HCV core protein expression by Western blot analysis. Detection of actin protein served 
as a protein loading control. Panel A (Fig. 1.5). depicts an example of a parent compound 
that lacked anti-HCV activity (9) and acquired anti-HCV activity upon methylation (10). 
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Panel B (Fig. 1.5). depicts an example of a parent compound that had anti-HCV activity 
(3) and decreased anti-HCV activity upon methylation (4). The graphs below panels A 
and B present quantitation of HCV core pixel intensity following normalization to actin 
pixel intensity, expressed as percent inhibition relative to DMSO controls. Graphs below 
panel A depict parent compounds that lacked anti-HCV activity (9, 11, 13) and acquired 
anti-HCV activity upon methylation (10, 12, 14). Graphs below panel B depict parent 
compounds that had anti-HCV activity (1, 3, 5, 7), and retained (2), decreased (4, 6), or 
enhanced (8) anti-HCV activity upon methylation. Doses used were derived from toxicity 
data and were selected to be in the non-toxic range for each compound.  
28 
 
 
 
Figure 1.5. Antiviral profile of parent and 7-O-methyl flavonolignans. 
Concentrations for compounds 1, 3, and 5: 6.2, 20.7, 62.1 µM 
Concentrations for compounds 2, 4, 6, and 14: 0.8, 2.7, 8.0 µM 
Concentrations for compounds 7 and 8: 1.6, 5.4, 16.1 µM 
Concentrations for compounds 9, 11, 12 and 13: 12.4, 41.4, 124.2 µM 
Concentrations for compound 10: 6.0, 20.1, 60.3 µM 
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1.3.2. Inhibition of drug metabolizing enzymes  
The propensity of methylation at the 7-O position to alter drug interaction liability 
was evaluated by testing all compounds as inhibitors of drug metabolizing enzymes using 
the probe substrates (S)-warfarin (CYP2C9; Fig. 1.6), midazolam (CYP3A; Fig. 1.7), and 
4-methylumbelliferone (UGT; Fig. 1.8) and human liver or intestinal microsomes (HLM 
or HIM, respectively). Although CYP2C9 and CYP3A are expressed in both the human 
intestine and liver,114  intestinal CYP2C9 has not yet been shown to have clinical impact 
on drug disposition in vivo. As such, HLM were selected for (S)-warfarin 7-
hydroxylation incubations, whereas HIM were selected for midazolam 1′-hydroxylation 
incubations. 
 All flavonolignans and 7-O-methylated analogues showed concentration-
dependent inhibition (10 vs. 100 μM, p<0.05) of the tested enzymatic activities (Figs. 
1.6-1.8), except for isosilybin A (5) against CYP2C9 activity (Fig. 1.6). The parent vs. 
methylated analogue pairs (at 100 µM) differed in inhibition potency (p<0.05) with the 
following exceptions: silybin B (3) vs. 7-O-methylsilybin B (4) (CYP2C9), silydianin 
(13) vs. 7-O-methylsilydianin (14) (CYP3A), silychristin (9) vs. 7-O-methylsilychristin 
(10) (CYP3A and UGT), and isosilybin B (7) vs. 7-O-methylisosilybin B (8) (UGT). 
Amongst the analogue series, compounds with an “iso” configuration inhibited the CYP 
enzymes (Figs. 1.6 and 1.7) to a greater extent. For example, relative to the control, 7-O-
methylisosilybin A (6), 7-O-methylisosilybin B (8), and 7-O-methylisosilychristin (12) 
were more potent against CYP2C9 and CYP3A activities than 7-O-methylsilybin A (2), 
7-O-methylsilybin B (4), and 7-O-methylsilychristin (10). 
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Compared to inhibition of the CYPs, inhibition of UGT was less extensive (Fig. 
1.8). However, in general, the parent compounds were more potent than the analogues. 
For example, silybin A (1), silybin B (3), and silydianin (13) were more potent 
(maximum extent of inhibition, 44%) than the respective methylated analogues (i.e. 2, 4, 
and 14 with a maximum extent of inhibition, 23%), suggesting that methylation reduced 
activity against UGT. One exception was 7-O-methylisosilychristin (12), which was more 
potent than isosilychristin (11), which each inhibited by up to 41% and 24%, respectively 
(p<0.05). CYP2C9 activity was most sensitive to the compounds, both parent and 
analogues, followed by CYP3A and UGT activity (up to 91%, 72%, and 44% inhibition, 
respectively). In summary, 7-O-methylation of isolated flavonolignans from milk thistle 
modulated drug interaction potential in vitro, highlighting the importance of this 
metabolically labile site and providing mechanistic insight into the enzyme-ligand 
interaction. 
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 Figure 1.6. Effects of selected flavonolignans (black) and 7-O-methylated analogues 
(gray) on CYP2C9-mediated (S)-warfarin 7-hydroxylation in human liver microsomes 
(HLM). Bars and error bars denote means and SDs, respectively, of triplicate incubations. 
*p < 0.05, 10 versus 100 µM; #p < 0.05, flavonolignan versus 7-O-methylated analogue 
at 100 µM (two-way ANOVA with Bonferroni adjustment). 
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Figure 1.7. Effects of selected flavonolignans (black) and 7-O-methylated analogues 
(gray) on CYP3A-mediated midazolam 1′-hydroxylation in human intestinal microsomes 
(HIM). Bars and error bars denote means and SDs, respectively, of triplicate incubations. 
*p < 0.05, 10 versus 100 µM; #p < 0.05, flavonolignan versus 7-O-methylated analogue 
at 100 µM (two-way ANOVA with Bonferroni adjustment). 
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Figure 1.8. Effects of selected flavonolignans (black) and 7-O-methylated analogues 
(gray) on UGT-mediated 4-methylumbelliferone (4-MU) glucuronidation in human liver 
microsomes (HLM). Bars and error bars denote means and SDs, respectively, of triplicate 
incubations. *p < 0.05, 10 versus 100 µM; #p < 0.05, flavonolignan versus 7-O-
methylated analogue at 100 µM (two-way ANOVA with Bonferroni adjustment). 
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1.4. Conclusions  
In summary, a series of 7-O-methylflavonolignan derivatives have been 
synthesized selectively, and this study is the first to examine methylation of all seven of 
the major flavonolignans in silymarin. All the derivatives showed cytotoxic effects 
against human hepatoma cells. The most potent analogue was 7-O-methylsilybin A, 
which exhibited an IC50 value of 9.5 µM compared with natural silybin A with an IC50 
value of 80 µM. In terms of anti-HCV activity, parent compounds with minimal to no 
antiviral activity (i.e., 9, 11, 13) showed increased antiviral activity when converted to the 
7-O-methyl derivatives. For these compounds, acquisition of antiviral activity by 7-O-
methylation was associated with enhanced cytotoxicity. In contrast, parent compounds 
with anti-HCV activity either retained (1), decreased (3, 5), or slightly increased (7) 
activity upon methylation. 
7-O-Methylation differentially modified the inhibitory potency of flavonolignans 
towards drug metabolizing enzymes, with compounds demonstrating increased, 
decreased, or no change in inhibitory potency depending upon the enzyme system 
investigated. Although a consistent pattern was not observed regarding inhibition potency 
towards the various drug metabolizing enzymes, the differences observed between parent 
and analogue suggested the importance of the 7-position. Cumulatively, these data 
suggested that silymarin-derived compounds exert pleiotropic effects on cells. Ongoing 
efforts are focusing on how these compounds affect cellular metabolic processes that 
culminate in cytotoxicity, antiviral activity, and drug metabolism inhibition. 
 
35 
 
1.5. Experiments 
1.5.1. General experimental procedures 
1.5.1.1. Solvents and Reagents 
All solvents and reagents were obtained from Sigma-Aldrich or Fisher Scientific 
and were used without further purification. All reactions were carried out in oven-dried 
glassware under N2 atmosphere. Reactions temperature 0 °C was carried out on water-ice, 
rt refers to room temperature 20-25 °C and 40-80 °C was adjusted using oil bath control. 
DIBAL-H was transferred using oven-dried stainless steel cannulating needles through 
rubber septa. 
1.5.1.2. Instruments 
HPLC: analytical and preparative HPLC were carried out on Varian Prostar 
HPLC systems equipped with Prostar 210 pumps and a Prostar 335 photodiode array 
detector (PDA), with data collected and analyzed using Galaxie Chromatography 
Workstation software (version 1.9.3.2). For preparative HPLC, a YMC ODS-A (5 μm, 
250 × 20 mm; Waters Corp.) column was used at a 7 mL/min flow rate and a 
Phenomenex PFP (pentafluorophenyl propyl; 5 μm; 250 × 21 mm) column was used at a 
21.2 mL/min flow rate. For analytical HPLC, a YMC ODS-A (5 μm; 150 × 4.6 mm) 
column and a PFP (5 μm; 150 × 4.6 mm) column were used, both at a 1 mL/min flow 
rate.  
UPLC: UPLC analysis was carried out on a Waters Acquity system with data collected 
and analyzed using Empower software (build 2154; Waters Corp., Milford, MA, USA). 
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Reversed-phase high-strength silica (HSS T3) trifunctional C18 alkyl phase bonded (1.8 
μm; 2.1 x 100mm; Waters Corp.) column was used with a 0.60 ml/min flow rate at 50 °C. 
Flash chromatography: Flash chromatography was performed on a Teledyne ISCO 
CombiFlash Rf (Teledyne-Isco, Lincoln, NE, USA) using a 40-g or 12-g Silica Gold 
column and monitored by UV and evaporative light-scattering detectors. 
 NMR spectrometry: All NMR experiments were conducted in DMSO- d6 at 30 °C  or 
Acetone-d6 using a JEOL ECA-500 (JEOL Ltd., Tokyo, Japan) (operating at 500 MHz 
for 1H and 125 MHz for 13C).  
HRESIMS data of compounds 2, 4, 6, 8, 10, 12 and 14 were measured on a LTQ 
Orbitrap XL mass spectrometer (Thermo Scientific, Bremen, Germany) using an 
electrospray ionization (ESI) source coupled to a Q-TOF Premier mass spectrometer 
(Waters Corp., Milford, MA, USA) in negative ionization mode via a liquid 
chromatographic/autosampler system that consisted of an Acquity UPLC system (Waters 
Corp.). Compounds 1′, 2′, 3′ and 4′ were taken using electrospray ionization (ESI) source 
in negative ionization mode. HRMS of 4-(3-Hydroxyprop-1-ynyl)-2-methoxyphenol was 
measured using an atmospheric pressure chemical ionization source (APCI) under direct 
infusion flow conditions in positive mode ionization.  
Optical rotation: was acquired on a Rudolph Research Autopol® III polarimeter. 
UV:  all data were acquired on and a Varian Cary 3 UV-Vis spectrophotometer. 
Centrifuge: eppendorf centrifuge 5415 C, 14,000 rpm.  
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1.5.2. Chemistry and Synthesis  
The individual flavonolignans were isolated from milk thistle extract (silymarin) 
in >98% purity as described in detail previously.108  
1.5.2.1.  7-O-Methylsilybin A (2)  
 
 
 
Scheme 1.1. Synthesis of 7-O-Methylsilybin A (2). 
 
 
To a 150 mL three-neck round-bottom flask, silybin A (122 mg, 0.253 mmol) and 
K2CO3 (293 mg, 2.03 mmol) were dissolved in acetone (80 mL, 0.003 M). After stirring 
for 10 min, CH3I (244 μL, 3.95 mmol) was added dropwise. The reaction mixture was 
heated at reflux under N2 for 3 h and monitored by HPLC. After cooling to rt, the 
reaction was quenched by the addition of 2% aqueous HCl (pH 1.5) and diluted with H2O 
(125 mL). The mixture was extracted with EtOAc (2 × 80 mL). The organic phases were 
combined and dried over Na2SO4, filtered, and then the solvent was removed under 
reduced pressure. The compounds were purified as described in Fig. 1.9.   Yield: 51 mg, 
41%; white solid; 
38 
 
 	 : + 20 (c 0.1, MeOH);  
UV (MeOH) max (log ):  218 (4.2), 287 (4.1) nm;  
CD (MeOH) ext ():  237 (-3.3), 296 (-9.2), 330 (1.7) nm; see Fig. 1.58 
 1H  NMR (500 MHz, DMSO-d6):   δ = 3.34 (m, 1H, H-9''b), 3.53 (ddd,  J = 10.3, 5.2, 
2.3 Hz, 1H, H-9''a), 3.77 (s, 3H, 3''-OCH3), 3.78 (s, 3H, 7-OCH3), 4.18 (ddd, J = 7.5, 4.6, 
2.3 Hz, 1H, H-8''), 4.69 (dd, J = 11.5, 6.3 Hz, 1H, 3-H), 4.91 (d, J = 7.5 Hz, 1H, H-7''), 
4.98 (dd, J = 5.7, 5.2 Hz, OH-9''), 5.14 (d, J = 11.5 Hz, 1H, 2-H), 5.90 (d, J = 6.3 Hz, 3-
OH), 6.10 (d, J = 1.7 Hz, 1H, H-8), 6.12 (d, J = 1.7 Hz, 1H, H-6), 6.80 (d, J = 8.6 Hz, 1H, 
H-5''), 6.86 (dd, J = 8.6, 1.8 Hz, 1H, H-6''), 6.98 (d, J = 8.6 Hz, 1H, H-5'),  7.01 (dd, J = 
8.6, 1.7 Hz, 1H, H-6'), 7.03 (d, J = 1.8 Hz, 1H, H-2''), 7.10 (d, J = 1.7 Hz, 1H, H-2'), 9.19 
(s, 4''-OH ), 11.86 (s, 5-OH) (see, Tables 1.1 and Fig. 1.10). 
 13C  NMR (125 MHz, DMSO-d6): δ 55.7 (3′′-OCH3), 60.2 (C-9′′), 71.5 (C-3), 75.9 (C-
7′′), 78.1 (C-8′′), 82.7 (C-2), 93.9 (C-8), 95.0 (C-6), 101.4 (C-4a), 111.6 (C-2′′), 115.3 (C-
5′′), 116.4 (C-5′), 116.7 (C-2′),  120.6 (C-6′′), 121.5 (C-6′), 127.5 (C-1′′), 129.9 (C-1′), 
143.3 (C-3′), 143.7 (C-4′), 147.0 (C-4′′), 147.6 (C-3′′), 162.4 (C-8a), 163.0 (C-5), 167.6 
(C-7), 198.5 (C-4),  see Tables 1.3 and Fig. 1.11;  
HSQC data: H-2→C-2; H-3→C-3; H-6→C-6; H-8→C-8; H-2'→C-2'; H-5'→C-5'; H-
6'→C-6'; H-2''→C-2''; H-5''→C-5''; H-6''→C-6'';  H-7''→C-7''; H-8''→C-8''; H-9''a→C-
9''; H-9''b→C-9''; OCH3-7→C-7; OCH3-3''→C-3'' (see Fig.1.12).  
HMBC data: HMBC data, H-3→C-2; OH-3→C-2, 3, 4; OH-5→C-5, 6, 4a; H-6→C-7,  
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8; OCH3-7→C-7; H-8→C-8a, 4a; H-2'→C2, 1', 4'; H-6'→C-4'; H-5'→C-4'; H-8''→C-7''; 
H-7''→C-8''; H-9''→C-7''; H-2''→C-3'', 6''; OCH3-C3''→C3''; OH-4''→C-4'', 5''; H-5''→C-
1'', 3''; H-6''→C-1'' see Figs. 1.13 and 1.14;  
HRESIMS m/z: 495.1281 [M-H]- (calcd for C26H23O10 495.1297; see Fig. 1.15).   
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Analytical method: 30:70 to 50:50 CH3CN:H2O (0.1% formic acid) over 30 min at a 1 
mL/min flow rate (PFP column) 
 
 
 
Separation method: PFP (5 µm; 250 × 21 mm) column was used at 30:70 to 50:50 
CH3CN:H2O (0.1% formic acid) over 30 min at a 21.2 mL/min flow rate 
 
 
Figure 1.9. HPLC chromatograms of crude reaction mixtures (a), purified 7-O-
methylsilybin A (b) at 288 nm and preparative HPLC (c) 
a 
b 
c 
99.85 %
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Figure 1.10. 1H NMR spectra (500 MHz, 30 °C) of silybin A (1) and 7-O-methylsilybin A (2) in DMSO-d6 
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Figure 1.11. 13C NMR spectra (125 MHz, 30 °C) of silybin A (1) and 7-O-methylsilybin A (2) in DMSO-d6 
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Figure 1.12. HSQC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylsilybin A (2) showing the key correlation 
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Figure 1.13. HMBC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylsilybin A (2) showing the key correlation between the 
methoxy protons and C-7 
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Figure 1.14. Key HMBC correlations of 7-O-methylsilybin A (2) 
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Figure 1.15. HRESIMS m/z 495.1281 [M-H]- of 7-O-methylsilybin A (2) 
47 
 
1.5.2.2. 7-O-Methylsilybin B (4)  
 
 
 
Scheme 1.2. Synthesis of 7-O-Methylsilybin A (2). 
 
 
In a manner that was otherwise consistent with the preparation and purification of 
2, compound 3 was reacted with 15 equivalents of CH3I at reflux for 3.5 h to yield 
compound 4. The compounds were purified as described in Fig. 1.16. Yield: 10 mg, 33%; 
white solid; 
 
 	:  + 7.7 (c 0.2, MeOH);  
UV (MeOH) max (log ): 230 (4.0) , 287 (4.0) nm;  
CD (MeOH) ext (): 230 (8.6), 296 (-9.2), 334 (1.3) nm; see Fig. 1.58. 
1H  NMR (500 MHz, DMSO-d6 at 30 °C):   δ = 3.34 (m, 1H, H-9''b), 3.54 (ddd,  J =  
12.0, 5.2, 2.3 Hz, 1H, H-9''a), 3.77 (s, 3H, 3''-OCH3), 3.78 (s, 3H, 7-OCH3), 4.17 (ddd, J  
= 7.5, 4.6, 2.3 Hz, 1H, H-8''), 4.67 (dd, J = 11.5, 6.3 Hz, 1H, 3-H), 4.91 (d, J = 7.5 Hz,  
1H, H-7''), 4.98 (dd, J = 5.7, 5.2 Hz, OH-9''), 5.14 (d, J = 11.5 Hz, 1H, 2-H), 5.89 (d, J = 
6.3 Hz, 3-OH), 6.10 (d, J = 2.3 Hz, 1H, H-8), 6.12 (d, J = 2.3 Hz, 1H, H-6), 6.80 (d, J = 
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8.0 Hz, 1H, H-5''), 6.86 (dd, J = 8.0, 1.7 Hz, 1H, H-6''), 6.98 (d, J = 8.0 Hz, 1H, H-5'),  
7.02 (dd, J = 8.0, 2.3 Hz, 1H, H-6'), 7.04 (d, J = 1.7 Hz, 1H, H-2''), 7.10 (d, J = 2.3 Hz, 
1H, H-2'), 9.18 (s, 4''-OH ), 11.87 (s, 5-OH) (see, Tables 1.1 and Fig. 1.17). 
13C NMR (125 MHz, DMSO-d6): δ 55.7 (3′′-OCH3), 60.2 (C-9′′), 71.5 (C-3), 75.9 (C-
7′′), 78.1 (C-8′′), 82.7 (C-2), 93.9 (C-8), 94.9 (C-6), 101.4 (C-4a), 111.6 (C-2′′), 115.3 (C-
5′′), 116.4 (C-5′), 116.7 (C-2′),  120.5 (C-6′′), 121.2 (C-6′), 127.5 (C-1′′), 130.0 (C-1′), 
143.2 (C-3′), 143.7 (C-4′), 147.0 (C-4′′), 147.6 (C-3′′), 162.4 (C-8a), 163.0 (C-5), 167.6 
(C-7), 198.5 (C-4). 1H and 13C NMR data, see Tables 1.3 and Fig. 1.18;  
HSQC data: H-2→C-2; H-3→C-3; H-6→C-6; H-8→C-8; H-2'→C-2'; H-5'→C-5'; H-
6'→C-6'; H-2''→C-2''; H-5''→C-5''; H-6''→C-6'';  H-7''→C-7''; H-8''→C-8''; H-9''a→C-
9''; H-9''b→C-9''; OCH3-7→C-7; OCH3-3''→C-3'' (see, Fig. 1.19). 
HMBC data: HMBC data, H-2→C-3, 4, 1', 2', 6'; H-3→C-2, 4, 1'; OH-3→C-2, 3 , 4; 
OH-5→C-5, 8, 4a; H-6→C-5, 7, 4a; H-8→C-5, 6; H-2'→C-2, 3', 6'; H-5'→C-1', 3'; H-
6'→C-2, 2', 3', 4'; H-8''→C-7'', 2'', 6''; H-2''→C-8'' , 3'', 6''; H-5''→C-1'', 3''; H-6''→C-2'', 
8'', 4''  see Figs. 1.20 and 1.21;  
HRESIMS m/z: 495.1290 [M-H]- (calcd for C26H23O10 495.1297; see Fig. 1.22).   
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Analytical method: 30:70 to 50:50 CH3CN:H2O (0.1% formic acid) over 30 min at a 1 
mL/min flow rate (PFP column). 
 
 
Separation method: PFP (5 µm; 250 × 21 mm) column was used at 20:80 to 40:60 
CH3CN:H2O (0.1 % formic acid) over 30 min at a 21.2 mL/min flow rate. 
 
 
Figure 1.16. HPLC chromatograms of crude reaction mixtures (a), purified 7-O-
methylsilybin B (b) at 288 nm and preparative HPLC (c). 
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Figure 1.17. 1H NMR spectra (500 MHz, 30 °C) of silybin B (3) and 7-O-methylsilybin B (4) in DMSO-d6 
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Figure 1.18. 13C NMR spectra (125 MHz, 30 °C) of silybin B (3) and 7-O-methylsilybin B (4) in DMSO-d6 
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Figure 1.19. HSQC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylsilybin B (4) showing the key correlation 
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Figure 1.20. HMBC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylsilybin B (4) showing the key correlation between the 
methoxy protons and C-7 
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Figure 1.21. Key HMBC correlations of 7-O-methylsilybin B (4). 
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Figure 1.22. HRESIMS m/z 495.1290 [M-H]- of 7-O-methylsilybin B (4) 
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1.5.2.3. 7-O-Methylisosilybin A (6)  
 
 
 
Scheme 1.3. Synthesis of 7-O-Methylisosilybin A (6). 
 
 
In a manner that was otherwise consistent with the preparation and purification of 
2, compound 5 was reacted with 2 equivalents of CH3I at 30 °C for 2.5 h to yield 
compound 6. The compounds were purified as described in Fig. 1.23.                                    
Yield: 22 mg, 21%; white solid; 
 
 
 	: + 46 (c 0.1, MeOH);  
UV (MeOH) max (log ): 214 (4.1), 287 (4.0) nm; 
 CD (MeOH) ext (): 236 (-0.9), 296 (-5.7), 331 (0.7) nm; see Fig. 1.58 
1H  NMR (500 MHz, DMSO-d6):   δ = 3.33 (m, 1H, H-9''b), 3.53 (ddd,  J = 12.0, 5.2, 
2.3 Hz, 1H, H-9''a), 3.77 (s, 3H, 3''-OCH3), 3.79 (s, 3H, 7-OCH3), 4.17 (ddd, J = 7.5, 4.0,  
2.3 Hz, 1H, H-8''), 4.66 (dd, J = 10.9, 6.3 Hz, 1H, 3-H), 4.91 (d, J = 7.5 Hz, 1H, H-7''),  
4.97 (dd, J = 5.7, 4.6 Hz, OH-9''), 5.16 (d, J = 11.5 Hz, 1H, 2-H), 5.91 (d, J = 6.3 Hz, 3- 
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OH), 6.12 (d, J = 2.3 Hz, 1H, H-8), 6.13 (d, J = 2.3 Hz, 1H, H-6), 6.80 (d, J = 8.0 Hz, 1H, 
H-5''), 6.85 (dd, J = 8.0, 1.7 Hz, 1H, H-6''), 6.94 (d, J = 8.6 Hz, 1H, H-5'),  6.99 (dd, J = 
8.6, 2.3 Hz, 1H, H-6'), 7.00 (d, J = 1.7 Hz, 1H, H-2''), 7.11 (d, J = 2.3 Hz, 1H, H-2'), 9.18 
(s, 4''-OH ), 11.87 (s, 5-OH) ; (see, Tables 1.1 and Fig. 1.24). 
13C  NMR (125 MHz, DMSO-d6): δ 55.7 (3′′-OCH3), 60.2 (C-9′′), 71.6 (C-3), 75.9 (C-
7′′), 78.0 (C-8′′), 82.7 (C-2), 93.9 (C-8), 95.0 (C-6), 101.4 (C-4a), 111.7 (C-2′′), 115.3 (C-
5′′), 116.5 (C-5′), 116.6 (C-2′),  120.5 (C-6′′), 121.0 (C-6′), 127.5 (C-1′′), 130.2 (C-1′), 
142.9 (C-3′), 143.9 (C-4′), 147.0 (C-4′′), 147.6 (C-3′′), 162.4 (C-8a), 163.0 (C-5), 167.6 
(C-7), 198.5 (C-4). 1H and 13C NMR data, see Tables 1.3 and Fig.1.25;  
HSQC data : H-2→C-2; H-3→C-3; H-6→C-6; H-8→C-8; H-2'→C-2'; H-5'→C-5'; H-
6'→C-6'; H-2''→C-2''; H-5''→C-5''; H-6''→C-6'';  H-7''→C-7''; H-8''→C-8''; H-9''a→C-
9''; H-9''b→C-9''; OCH3-7→C-7; OCH3-3''→C-3'' (see Fig. 1.26). 
HMBC data: HMBC data, H-2→C-4; H-3→C-2, 4; OH-3→C-2, 3 , OH-5→C-6, 4a; H-
6→C-5 , OCH3-7→C-7; H-8a →C-7, 4a; H-2'→C2; H-6'→C-2, H-7''→C- 8'', 6'', OCH3- 
C3''→C3'';  H-5''→C-1''; OH-4''→C-4'', 5'', 3''. see Fig. 1.27 and 1.28;  
HRESIMS m/z: 495.1292 [M-H]- (calcd for C26H23O10 495.1297; see Fig 1.29).  
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Analytical method: 30:70 to 50:50 CH3CN:H2O (0.1% formic acid) over 30 min at a 1 
mL/min flow rate (PFP column). 
 
 
Separation method: PFP (5 µm; 250 × 21 mm) column was used at 30:70 to 50:50 
CH3CN:H2O (0.1% formic acid) over 30 min at a 21.2 mL/min flow rate. 
 
 
Figure 1.23. HPLC chromatograms of crude reaction mixtures (a), purified 7-O-
methylisosilybin A (b) at 288 nm and preparative HPLC (c). 
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Figure 1.24. 1H NMR spectra (500 MHz, 30 °C) of isosilybin A (5) and 7-O-methylisosilybin A (6) in DMSO-d6 
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Figure 1.25. 13C NMR spectra (125 MHz, 30°C) of isosilybin A (5) and 7-O-methylisosilybin A (6) in DMSO-d6 
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Figure 1.26. HMBC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylisosilybin A (6) showing the key 
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Figure 1.27. HMBC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylisosilybin A (6) showing the key correlation between 
the methoxy protons and C-7 
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Figure 1.28. Key HMBC correlations of 7-O-methylisosilybin A (6) 
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Figure 1.29. HRESIMS m/z 495.1292 [M-H]- of 7-O-methylisosilybin A (6) 
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1.5.2.4.  7-O-Methylisosilybin B (8)  
 
 
 
Scheme 1.4. Synthesis of 7-O-Methylisosilybin B (8). 
 
 
In a manner that was otherwise consistent with the preparation and purification of 
2, compound 7 was reacted with 4 equivalents of CH3I at 40 °C for 2.5 h to yield 
compound 8. The compounds were purified as described in Fig. 1.30.  Yield: 12 mg, 
24%; white solid;  
 
 	: 	-17.4 (c 0.09, MeOH);  
UV (MeOH) max (log ): 211 (4.1), 287 (3.8) nm; 
 CD (MeOH) ext (): 229 (1.8), 294 (-4.2), 331 (-0.1) nm; see Fig. 1.58 
 1H  NMR (500 MHz, DMSO-d6):   δ = 3.33 (m, 1H, H-9''b), 3.53 (ddd,  J = 10.0, 5.2, 
1.7 Hz, 1H, H-9''a), 3.77 (s, 3H, 3''-OCH3), 3.79 (s, 3H, 7-OCH3), 4.17 (ddd, J = 7.5, 4.6,  
1.7 Hz, 1H, H-8''), 4.67 (dd, J = 11.5, 6.3 Hz, 1H, 3-H), 4.92 (d, J = 7.5 Hz, 1H, H-7''), 
4.97 (dd, J = 5.2, 4.6 Hz, OH-9''), 5.16 (d, J = 11.5 Hz, 1H, 2-H), 5.91 (d, J = 6.3 Hz, 3-
OH), 6.12 (d, J = 2.3 Hz, 1H, H-8), 6.13 (d, J = 2.3 Hz, 1H, H-6), 6.80 (d, J = 8.0 Hz, 1H, 
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H-5''), 6.85 (dd, J = 8.2, 1.8 Hz, 1H, H-6''), 6.94 (d, J = 8.0 Hz, 1H, H-5'),  7.00 (dd, J = 
8.0, 1.7 Hz, 1H, H-6'), 7.01 (d, J = 1.8 Hz, 1H, H-2''), 7.11 (d, J = 1.7 Hz, 1H, H-2'), 9.18 
(s, 4''-OH ), 11.87 (s, 5-OH); (see, Tables 1.1 and Fig. 1.31). 
13C  NMR (125 MHz, DMSO-d6): δ 55.7 (3′′-OCH3), 60.2 (C-9′′), 71.6 (C-3), 75.9 (C-
7′′), 78.0 (C-8′′), 82.7 (C-2), 93.9 (C-8), 95.0 (C-6), 101.4 (C-4a), 111.7 (C-2′′), 115.3 (C-
5′′), 116.4 (C-5′), 116.5 (C-2′),  120.4 (C-6′′), 121.0 (C-6′), 127.5 (C-1′′), 130.2 (C-1′), 
142.9 (C-3′), 143.9 (C-4′), 147.0 (C-4′′), 147.6 (C-3′′), 162.4 (C-8a), 163.0 (C-5), 167.6 
(C-7), 198.4 (C-4). 1H and 13C NMR data, see Tables 1.3 and Fig. 1.32;  
HSQC data: H-2→C-2; H-3→C-3; H-6→C-6; H-8→C-8; H-2'→C-2'; H-6'→C-6'; H-
2''→C-2''; H-5''→C-5''; H-6''→C-6'';  H-7''→C-7''; H-8''→C-8''; H-9''a→C-9''; H-9''b→C-
9''; OCH3-7→C-7; OCH3-3''→C-3'' (see Fig. 1.33). 
HMBC data: HMBC data, H-2→C-3, 1', 6'; OH-5→C-5, 6; H-6→C-8, OCH3-7→C-7; 
H-8→C-4a; H-2'→C-4'; H-5'→C-4'; H-7''→C-1'', 6''; H-2''→C-3'' ; OH-4''→C-6'' ; H-
5''→C-4''; OCH3-C3''→C3''; H-6''→C-3''. (see Figs. 1.34 and 1.35);  
HRESIMS m/z: 495.1294 [M-H]- (calcd for C26H23O10 495.1297; see Fig 1.36).  
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Analytical method: 20:80 to 60:40 CH3CN:H2O (0.1 % formic acid) over 40 min. 
 
Separation method: gradient of 20:80 to 60:40 CH3CN:H2O (0.1 % formic acid) over 40 
min 60: 40 hold for 5 min. 
 
 
Figure 1.30. HPLC chromatograms of crude reaction mixtures (a), purified 7-O-
methylisosilybin B (b) at 288 nm and preparative HPLC (c). 
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Figure 1.31. 1H NMR spectra (500 MHz, 30 °C) of isosilybin B (7) and 7-O-methylisosilybin B (8) in DMSO-d6 
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Figure 1.32 13C NMR spectra (125 MHz, 30 °C) of isosilybin B (7) and 7-O-methylisosilybin B (8) in DMSO-d6 
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Figure 1.33. HSQC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylisosilybin B (8) showing the key correlation 
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Figure 1.34. HMBC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylisosilybin B (8) showing the key correlation between the 
methoxy protons and C-7 
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Figure 1.35. Key HMBC correlations of 7-O-methylisosilybin B (8) 
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Figure 1.36. HRESIMS m/z 495.1294 [M-H]- of 7-O-methylisosilybin B (8) 
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1.5.2.5. 7-O-Methylsilychristin (10)  
 
 
 
Scheme 1.5. Synthesis of 7-O-Methylsilychristin (10). 
 
 
In a manner that was otherwise consistent with the preparation and purification of 
2, compound 9 was reacted with 12 equivalents of CH3I at reflux for 2 h to yield 
compound 10. The compounds were purified as described in Fig. 1.37  Yield: 41 mg, 
40%; white solid; 
 
 	: +56.6 (c 0.06, MeOH);  
UV (MeOH) max (log ): 215 (4.0), 288 (3.8) nm; 
 1H  NMR (500 MHz, DMSO-d6):  δ = 3.47 (ddd, J = 12.6, 12.0, 6.9 Hz, 1H, H-8''), 3.63 
(ddd, J = 12.6, 10.9, 6.9 Hz, 1H, H-9''b), 3.72 (ddd,  J = 12.6, 10.9, 5.2 Hz, 1H, H-9''a), 
3.76 (s, 3H, 3''-OCH3), 3.78 (s, 3H, 7-OCH3), 4.58 (dd, J = 11.4, 6.3 Hz, 1H, H-3), 5.01 
(dd, J = 5.7, 5.2 Hz, OH-9''), 5.05 (d, J = 11.4 Hz, 1H, H-2), 5.46 (d, J = 6.9 Hz, 1H, H-
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7''), 5.81 (d, J = 6.3 Hz, OH-3), 6.09 (d, J = 2.3 Hz, 1H, H-8), 6.12 (d, J = 2.3 Hz, 1H, H-
6), 6.76 (d, J = 8.1 Hz, 1H, H-5''), 6.81 (dd, J = 8.1, 1.8 Hz, 1H, H-6''), 6.84 (d, J = 1.2 
Hz, 1H, H-2'), 6.88 (br s, 1H, H-6'), 6.96 (d, J = 1.8 Hz, 1H, H-2''), 9.02 (s, 4''-OH ), 
11.87 (s, 5-OH) (see, Tables 1.2 and Fig. 1.38).  
13C NMR (125 MHz, DMSO-d6): δ 53.9 (C-8′′), 55.6 (3′′-OCH3), 63.5 (C-9′′), 71.8 (C-
3), 83.4 (C-2), 87.5 (C-7′′), 93.8 (C-8), 94.9 (C-6), 101.4 (C-4a), 110.9 (C-2′′), 115.3 (C-
5′′), 115.4 (C-6′), 115.7 (C-2′), 118.7 (C-6′′), 129.1 (C-5′),  129.8 (C-1′), 132.4 (C-1′′), 
140.7 (C-4′), 162.4 (C-8a), 163.0 (C-5), 146.4 (C-3′), 147.7 (C-4′′), 148.1 (C-3′′), 167.5 
(C-7), 198.4 (C-4).  1H and 13C NMR data, see Tables 1.3 and Fig. 1.39;  
HSQC data: H-2→C-3, 4, 6'; H-3→C-2, 4; OH-5→C-6, 4a, 8a;  H-6→C-7; OCH3-
7→C-7; H-8→C-6, 7; H-2'→C-3', 6'; OH-3'→C-2', 4'; H-7''→C-9''; H-9'' →C-8''; H-
2''→C-7'', 6''; OCH3-3''→C3''; OH-4''→C-4'', 5''; H-5''→C-1' '(see Fig. 1.40; 
HMBC data: see Figs. 1.41 and 1.42;  
HRESIMS m/z: 495.1284 [M-H]- (calcd for C26H23O10 495.1297; see Fig. 1.43). 
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Analytical method: 20:80 to 36:64 CH3CN:H2O (0.1% formic acid) over 24 min. 
 
Separation method: gradient of 20:80 to 42:58 CH3CN:H2O (0.1% formic acid) over 45 
min hold 45:58 for 10 min. 
 
 
Figure 1.37. HPLC chromatograms of crude reaction mixtures (a), purified 7-O-
methylsilychristin (b) at 288 nm and preparative HPLC (c). 
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Figure 1.38. 1H NMR spectra (500 MHz, 30 °C) of silychristin (9) and 7-O-methylsilychristin (10) in DMSO-d6 
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Figure 1.39. 13C NMR spectra (125 MHz, 30 °C) of silychristin (9) and 7-O-methylsilychristin (10) in DMSO-d6 
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Figure 1.40. HSQC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylsilychristin (10) showing the key 
 
 
 
80 
 
Figure 1.41. HMBC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylsilychristin (10) showing the key correlation between 
the methoxy protons and C-7 
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Figure 1.42. Key HMBC correlations of 7-O-methylsilychristin (10) 
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Figure 1.43. HRESIMS m/z 495.1284 [M-H]- of 7-O-methylsilychristin (10) 
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1.5.2.6.  7-O-Methylisosilychristin (12) 
 
 
R = H [isosilychristin (11)]
R = CH3 [7-O-methylisosilychristin (12)]
CH3I, K2CO3
acetone
40 °C, 2 h
29% yield
O
OH
O
HOH2C
OCH3
O
RO
OH
OH
HO
 
Scheme 1.6. Synthesis of 7-O-Methylisosilychristin (12). 
 
 
In a manner that was otherwise consistent with the preparation and purification of 
2, compound 11 was reacted with 24 equivalents of CH3I at 40 °C for 2 h to yield 
compound 12. The compounds were purified as described in Fig. 1.44.  Yield: 15 mg, 
29%; white solid; 
 
	: 	+144.4 (c 0.05, MeOH);  
UV (MeOH) max (log ): 212 (4.1), 288 (3.7) nm.  
1H NMR (500 MHz, DMSO-d6): δ = 3.44 (m, 1H, H-9''b), 3.67 (m, 1H, H-8''), 3.68 (m, 
1H, H-9''a), 3.69 (s, 3H, 3''-OCH3), 3.80 (s, 3H, 7-OCH3), 4.67 (dd, J = 11.4, 6.9 Hz, 1H, 
H-3), 5.06 (dd, J = 6.5, 4.5 Hz, OH-9''), 5.22 (d, J = 11.4 Hz, 1H, H-2), 5.57 (d, J = 2.5 
Hz, 1H, H-7''), 5.81 (d, J = 6.9 Hz, OH-3), 6.11 (d, J = 2.0 Hz, 1H, H-8), 6.13 (d, J = 2.0 
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Hz, 1H, H-6), 6.69 (d, J = 8.5 Hz, 1H, H-5′′), 6.74 (d, J = 8.1 Hz, 1H, H-5'), 6.76 (d, J = 
8.5 Hz, 1H, H-6''), 6.86 (d, J = 2.0 Hz, 1H, H-2''), 6.97 (d, J = 8.1 Hz, 1H, H-6'), 8.99 (s, 
4''-OH ), 11.90 (s, 5-OH) ; (see, Tables 1.2 and Fig. 1.45). 
 13C NMR (125 MHz, DMSO-d6) δ 53.9 (C-8′′), 55.6 (3′′-OCH3), 63.5 (C-9′′), 71.8 (C-
3), 83.4 (C-2), 87.5 (C-7′′), 93.8 (C-8), 94.9 (C-6), 101.4 (C-4a), 110.9 (C-2′′), 115.3 (C-
5′′), 115.4 (C-6′), 115.7 (C-2′), 118.7 (C-6′′), 129.1 (C-5′),  129.8 (C-1′), 132.4 (C-1′′), 
140.7 (C-4′), 162.4 (C-8a), 163.0 (C-5), 146.4 (C-3′), 147.7 (C-4′′), 148.1 (C-3′′), 167.5 
(C-7), 198.4 (C-4). 1H and 13C NMR data, see Tables 1.2 and Figs. 1.46; 
 HSQC data: H-2→C-2; H-3→C-3; H-6→C-6; H-8→C-8; H-5'→C-5'; H-6'→C-6'; H-
2''→C-2''; H-5''→C-5''; H-6''→C-6'';  H-7''→C-7''; H-8''→C-8''; H-9''a→C-9''; H-9''b→C-
9''; OCH3-7→C-7; OCH3-3''→C-3'' (see, Fig. 1.47). 
HMBC data: see Figs. 1.48 and 1.49;   
HRESIMS m/z: 495.1284 [M-H]- (calcd for C26H23O10 495.1297; see Fig. 1.50). 
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Analytical method: 15:80 to 36:64 CH3CN:H2O (0.1 % formic acid) over 40 min.  
 
Separation method: gradient of 15: 85 to 36:64 over 50 min hold 36:64 for 10 min. 
 
Figure 1.44. HPLC chromatograms of crude reaction mixtures (a), purified 7-O-
methylisosilychristin (b) at 288 nm and preparative HPLC (c). 
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Figure 1.45. 1H NMR spectra (500 MHz, 30 °C) of isosilychristin (11) and 7-O-methylisosilychristin (12) in DMSO-d6 
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Figure 1.46. 13C NMR spectra (125 MHz, 30°C) of isosilychristin (11) and 7-O-methylisosilychristin (12) in DMSO-d6 
 
 
 
88 
 
Figure 1.47. HSQC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylisosilychristin (12) showing the key correlation 
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Figure 1.48. HMBC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylisosilychristin (12) showing the key correlation between 
the methoxy protons and C-7 
 
 
 
 
90 
 
Figure 1.49. Key HMBC correlations of 7-O-methylisosilychristin (12) 
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Figure 1.50. HRESIMS m/z 495.1284 [M-H]- of 7-O-methylisosilychristin (12) 
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1.5.2.7.  7-O-Methylsilydianin (14) 
 
 
 
Scheme 1.7. Synthesis of 7-O-Methylsilydianin (14). 
 
 
In a manner that was otherwise consistent with the preparation and purification of 
2, compound 13 was reacted with 12 equivalents of CH3I at reflux for 2 h to yield 
compound 14. The compounds were purified as described in Fig. 1.51. 
 Yield: 20 mg, 33%; white solid; 
 
 	: +157.9 (c 0.06, MeOH);  
UV (MeOH) max (log ): 207 (3.9), 288 (3.6) nm.  
1H NMR (500 MHz, DMSO-d6):   δ = 2.73 (br s, 1H, H-8''), 3.19 (dd, J = 6.9, 3.0 
Hz,1H, H-5'), 3.31 (br s, 1H, H-7''), 3.45 (dd, J = 4.0, 2.0 Hz, 1H, H-2'), 3.74 (s, 3H, 3''- 
OCH3), 3.78 (d, J = 8.0 Hz, 1H, H-9''b), 3.79 (s, 3H, 7-OCH3), 4.13 (dd, J = 8.0, 3.0 Hz, 
1H, H-9''a), 4.48 (dd, J = 10.4, 5.4 Hz, 1H, H-3), 4.91 (dd, J = 10.4 Hz, 1H, H-2), 6.01  
(d, J = 6.9 Hz, 1H, H-6'), 6.04 (d, J = 6.3 Hz, OH-3), 6.11 (d, J = 1.9 Hz, 1H, H-8), 6.12 
(d, J = 1.9 Hz, 1H, H-6), 6.56 (dd, J = 8.4, 1.9 Hz, 1H, H-6''), 6.64 (d, J = 8.4 Hz, 1H, H-
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5''), 6.76 (d, J = 1.9 Hz, 1H, H-2''), 3.17 (s, , OH-3'), 8.79 (s, , OH-4''), 11.77 (s, OH-5). 
(see, Tables 1.2 and Fig. 1.52).   
13C NMR (125 MHz, DMSO-d6):  δ 44.0 (C-8′′), 46.0 (C-7′′), 48.7 (C-2′), 53.3 (C-5′), 
55.4 (3′′-OCH3), 71.0 (C-3), 72.8 (C-9′′), 81.8 (C-2), 93.8 (C-8), 95.2 (C-6), 96.7 (C-3′), 
101.2 (C-4a), 112.4 (C-2′′), 115.0 (C-5′′), 120.3 (C-6′′), 124.0 (C-6′), 133.0 (C-1′′), 139.4 
(C-1′), 145.1(C-4′′), 132.4 (C-1′′), 147.2 (C-3′′), 162.0 (C-8a), 163.0 (C-5), 167.6 (C-7), 
197.6 (C-4), 201.9 (C-4′).  13C NMR data, (see, Tables 1.3 and Fig. 1.53). 
HSQC data: H-2→C-2; H-3→C-3; H-6→C-6; H-8→C-8; H-2'→C-2'; H-5'→C-5'; H-
6'→C-6'; H-2''→C-2''; H-5''→C-5''; H-6''→C-6'';  H-7''→C-7''; H-8''→C-8''; H-9''a→C-
9''; H-9''b→C-9''; OCH3-7→C-7; OCH3-3''→C-3'' (see Fig. 1.54). 
HMBC data: H-2→C-3, 1'; H-3→C-2; OH-3→C-2, 3; H-6→C-7, 4a, OCH3-7→C-7; H-
8→C-6, 8a; H-2'→C-4'; OH-3'→C-2'; H-5'→C-1', 4', 6'; H-6'→C-2', 4', 5' , H-7''→C-9'' , 
1'', 2'', 6'';  H-9''→C-7'', 8'', 3'; H-8''→C-3'; H-2''→C-7'', 3'', 6'', OCH3-3''→C3''; OH-
4''→C-3'', 5''; H-5''→C-1'', 3'', 4''; H-6''→C-7'' , 1'', 4'' (see Figs. 1.55 and 1.56).  
HRESIMS m/z:  495.1284 [M-H]- (calcd for C26H23O10 495.1297; see Fig. 1.57).  
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Analytical method: 20:80 to 36:64 CH3CN:H2O (0.1% formic acid) over 24 min. 
 
Analytical method: 20:80 to 36:64 CH3CN:H2O (0.1% formic acid) over 24 min. 
 
Figure 1.51. HPLC chromatograms of crude reaction mixtures (a), purified 7-O-
methylsilydianin (b) at 288 nm and preparative HPLC (c). 
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Figure 1.52. 1H NMR spectra (500 MHz, 30 °C) of silydianin (13) and 7-O-methylsilydianin (14) in DMSO-d6 
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Figure 1.53. 13C NMR spectra (125 MHz, 30 °C) of silydianin (13) and 7-O-methylsilydianin (14) in DMSO-d6 
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Figure 1.54. HSQC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylsilydianin (14) showing the key correlation  
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Figure 1.55. HMBC NMR spectrum (DMSO-d6, 30 °C) of 7-O-methylsilydianin (14) showing the key correlation between the 
methoxy protons and C-7 
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Figure 1.56. Key HMBC correlations of 7-O-methylsilydianin (14) 
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Figure 1.57. HRESIMS m/z 495.1284 [M-H]- of 7-O-methylsilydianin (14) 
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Figure 1.58. Circular Dichroism (CD) spectra of 7-O-methylflavonolignans 
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1.6.  Biological Assay  
1.6.1. Anti-proliferative assay 
The antiproliferative/cytotoxic activities of all compounds were examined against 
a human hepatoma cell line, Huh7.5.1,115 as described previously.116 Briefly, 10,000 cells 
per well were plated in 96-well plates, and following overnight incubation, were 
incubated with increasing concentrations of compounds. Cell viability was measured 72 h 
later using the ATPlite kit, as described previously,109 and an IC50 value was calculated 
by linear regression using GraphPad Prism.  
1.6.2. Anti-viral assay 
Cells (150,000) were plated in 12-well plates, and the next day cells were infected 
with JFH-1, a HCV that grows well in Huh7.5.1 cells, at a multiplicity of infection of 
0.05 focus forming units per cell. Virus inocula were removed 5 h post-infection and 
replaced with fresh medium containing test compounds. Protein lysates were harvested 
72 h later, and HCV proteins were detected by Western blot analyses as described 
previously.109 
1.6.3. Inhibition of drug metabolizing enzymes 
Milk thistle flavonolignans and 7-O-methylated analogues were evaluated as 
inhibitors of CYP2C9, CYP3A, and UGT activity using the probe substrates (S)-warfarin, 
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midazolam, and 4-methylumbelliferone (4-MU), respectively. Inhibition of CYP2C9 
activity. Incubation mixtures consisted of pooled HLM (0.1 mg/mL microsomal protein), 
(S)-warfarin (4 µM), flavonolignan or 7-O-methylated analogue (10 or 100 µM), and 
potassium phosphate buffer (100 mM, pH 7.4). The CYP2C9 inhibitor sulfaphenazole (1 
µM) was used as a positive control. Control incubation mixtures contained 0.75% MeOH 
(v/v) in place of flavonolignan/7-O-methylated flavonolignan or sulfaphenazole. 
Incubation mixtures were analyzed for 7-hydroxywarfarin by LC/MS-MS as described 
previously.117 Inhibition of CYP3A activity. Incubation mixtures consisted of pooled HIM 
(0.05 mg/mL microsomal protein), midazolam (4 µM), flavonolignans or 7-O-methylated 
analogue (10 or 100 µM), and potassium phosphate buffer (100 mM, pH 7.4) 
supplemented with magnesium chloride (3.3 mM). The CYP3A inhibitor ketoconazole (1 
µM) was used as a positive control. Control incubation mixtures contained 0.1% DMSO 
(v/v) in place of flavonolignan/7-O-methylated flavonolignan or ketoconazole. 
Incubation mixtures were analyzed for 1′-hydroxymidazolam by LC/MS-MS as described 
previously.118 Inhibition of UGT activity. Incubation mixtures consisted of pooled HLM 
(0.4 mg/mL microsomal protein), 4-MU (100 µM), flavonolignan or 7-O-methylated 
analogue (10 or 100 µM), bovine serum albumin (BSA, 0.05%), and Tris-HCl buffer (0.1 
M, pH 7.5) supplemented with magnesium chloride (5 mM). The UGT inhibitor 
diclofenac (400 µM) was used as a positive control. Control incubation mixtures 
contained 0.2% MeOH (v/v) in place of flavonolignan/7-O-methylated flavonolignan or 
diclofenac. Incubation mixtures were analyzed for 4-MU depletion by fluorescence as 
described previously.119 
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Data were analyzed statistically using SigmaStat (version 3.5; Systat Software, Inc., San 
Jose, CA) and are presented as means ± SDs of triplicate incubations. Concentration-
dependent inhibition of each flavonolignan/7-O-methylated analogue and comparisons 
between flavonolignan and 7-O-methylated analogue at 100 µM were evaluated by two-
way analysis of variance (ANOVA) with Bonferroni adjustment for multiple 
comparisons; p < 0.05 was considered significant. 
1.7. Development of Flavonolignans Separation Using Pentaflurophenyl Propyl 
(PFP) Column  
1.7.1. Introduction 
Endcapped octadecyl silica (ODS) C18 column played an important role in the 
separation of flavonolignans diastereoisomers and it was used for a long time. Separation 
on the pentafluorophenyl propyl (PFP) column showed good resolution, enhanced the 
separation and helped to remove some unknown compounds. The PFP column has some 
properties for solute retention on fluorinated phases including: dipole–dipole interactions;  
π-π interactions; charge transfer and ion-exchange mechanism.121  This column helped to 
remove small impurities that were not separated using YMC C18. It is important to note 
that there is no separation for diastereoisomers on PFP.  
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1.7.2. Separation Methods 
To purify the compounds, two different reverse-phase columns [ODS-A C18 (5  
µm; 250 × 20 mm) and PFP (5 µm; 250 × 21 mm)] were examined. Accordingly, each 
flavonolignan was purified until >98% pure, as measured by analytical HPLC.  Silybin B 
were purified using a gradient of 20:80 to 40:60 CH3CN:H2O (0.1 % formic acid) over 20 
min and hold 5 min. Isosilybin B was purified using a gradient of 20:80 to 40:60 
CH3CN:H2O (0.1 % formic acid) over 45 min.  Silychristin and isosilychristin fraction 
mixture was purified using two methods first, 15:85 to 36:64 CH3CN:H2O (0.1 % formic 
acid) over 40 min. Second method was using a gradient of 20:80 to 42:58 CH3CN:H2O 
(0.1% formic acid) over 35 min. 
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Analytical method: gradient of 20: 80 to 40:60 CH3CN:H2O (0.1% formic acid) over 20 
min 40: 60 hold for 5 min, using PFP column  
 
 
 
Separation method: gradient of 20: 80 to 40:60 CH3OH:H2O over 20 min 40: 60 hold 
for 5 min, using PFP column  
 
 
Figure 1.59. HPLC chromatograms analytical and separation of silybin A and silybin B at 
288 nm 
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Analytical method: gradient of 20: 80 to 60:40 CH3CN:H2O (0.1% formic acid) over 
over 30 min using PFP column  
 
 
 
 
Separation method: gradient of 20: 80 to 60:40 CH3CN:H2O (0.1% formic acid) over 
over 45 min using PFP column  
 
 
Figure 1.60. HPLC chromatograms analytical and separation of isosilybin A and 
isosilybin B at 288 nm 
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108 
 
Analytical method: gradient of 20: 80 to 60:40 CH3CN:H2O (0.1% formic acid) over 
over 30 min using PFP column 
 
 
 
Analytical method: gradient of 5: 90 to 45:55 CH3CN:H2O (0.1% formic acid) over over 
30 min using PFP column  
 
 
Figure 1.61. HPLC chromatograms analytical of silychristin, isosilychristin and taxifolin 
at 288 nm 
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Separation method A: 15: 75 to 36:64 CH3CN:H2O (0.1% formic acid) over 40 min 
using PFP column 
 
 
Separation method B: 20: 80 to 42:58 CH3CN:H2O (0.1% formic acid) over over 35 
min using PFP column. 
 
 
Figure 1.62. HPLC chromatograms separation of silychristin and isosilychristin at 288 
nm 
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CHAPTER II 
MECHANISTIC STUDY OF THE BIOMIMETIC SYNTHESIS OF 
FLAVONOLIGNAN DIASTEREOISOMERS 
 
     This project was submitted for publication. 
 
 
2.1. Introduction  
2.1.1. Flavonolignans biosynthetic hypothesis 
 Flavonolignans (1-7, Fig. 2.1) are characterized by the presence of a flavonoid 
moiety (taxifolin) that is linked to a phenylpropane (coniferyl alcohol).6,121,122 Within 
flavonolignans, two pairs of trans-disteroisomers have been characterized with respect to 
the relative configuration at the C-7″ and C-8″ in the 1,4-benzodioxane ring, silybinin 
(silybin A and silybin B) and isosilybinin (isosilybin A and isosilybin B).7,20,62 In 
contrast, silychristin and isosilychristin have dihydrobenzofuran rings and silydianin 
contains a structurally more complex bicyclo[2.2.2]octenone with a hemiketal (Fig. 2.1)6 
It has been proposed that flavonolignans are biosynthetically derived from an oxidative 
coupling reaction of coniferyl alcohol and taxifolin (Scheme 2.1).3,123-126 
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The mechanisms presented are typically based on Freudenberg’s hypothesis for 
the synthesis of lignans from coniferyl alcohol. For the flavonoligans, this involves single 
electron oxidation of both coniferyl alcohol and taxifolin individually and then 
combination of these two radicals to synthesize silibinin and isosilibinin. Besides free 
radical coupling reaction, Diels-Alder reaction was proposed as a possible reaction for 
silydianin formation.12    
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Figure 2.1. Flavonolignans Isolated from Silymarin and their Precursors. 
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Scheme 2.1. Previously Proposed Flavonolignans Biosynthesis Theory. 
 
 
2.1.2 Biomimetic synthesis of flavonolignans 
The biomimetic synthesis is a reaction or sequence of reactions that mimic the 
biosynthetic pathway.127,128 The concept of biomimetic synthesis was firstly introduced in 
1917 by Sir Robert Robinson (1886-1975, Nobel Prize 1947) at Oxford University and is 
still considered.130 Robinson’s synthesis of tropinone, an alkaloid, from succindialdehyde 
(1), methylamine and acetone dicarboxylic acid (2) under Mannich reaction conditions 
was the first example of biomimetic synthesis.128 This biomimetic strategy reduced 
Willstätter’s 1903 seventeen step synthesis starting with suberone into a single step.127,129  
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Scheme 2.2. Robinson's Biomimetic Synthes of Tropinone. 
 
 
In the area of flavonolignans synthesis, the first total synthesis was before the 
correction of silybin structures in 1971 by Mishima and co-worker and later it was found 
out this synthesis was of isosilibinin.130,131  In 1985, Tanaka and co-worker achieved the 
first total synthesis of silybinin. Soon after, the synthesis of silychristin was reported in 
1988, again by the Tanaka group. The biomimetic synthesis of flavonolignans were first 
reported by Merlini and co-worker in 1979.131 In this synthesis they used silver oxide to 
promote the reaction of taxifolin with coniferyl alcohol to yield a 1: 1 mixture of 
silybinin and isosilybinin. This synthesis was before isolation and structure elucidation of 
flavonolignans 1-4 (Fig. 2.1).   
Recently, Guz, 2000, used Merlini’s biomimetic method to synthesize 
hydnocarpin, structurally related flavonolignans with 1,4-benzodioxane ring system, 
which isolated from hydnocarpus wightiana.132,133 In addition to using silver carbonate to 
oxidize the starting materials, they used horseradish peroxidase (HRP) enzyme to 
promote the reaction of luteolin with coniferyl alcohol to yield a racemic mixture of 
hydnocarpin and hydnocarpin-D.  Reactions under Ag2CO3 oxidation yielded a mixture 
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having the major product hydnocarpin-D and the horseradish peroxidase (HRP) reactions 
major product hydnocarpin (Scheme 2.3).133 
 
 
Scheme 2.3. Biomimetic Synthesis of Hydnocarpin and Hydnocarpin-D. 
 
 
Interestingly, most of the reported mechanisms for this transformation131,134 involve 
single electron oxidation of both coniferyl alcohol and taxifolin individually and then 
combination of these two radicals to synthesize silybinin and isosilybinin (Scheme 2.4, 
option 1).   
While there is a slight possibility that this type of pathway could occur in an 
enzyme pocket, the probability of two radicals being formed in solution from silver oxide 
and then combining productively is beyond the realm of possibilities. This is due to the 
fact that the concentration of each radical will be extremely low, due to the inherent 
reactivity of the reactive intermediates.  Since the rate of the reaction is directly 
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correlated to the concentration of each radical, the reaction rate will be essentially zero.  
Given that this unlikely biosynthetic proposal, often cited as Freudberg’s proposal even 
though he did not appear to ever propose such a mechanism, is still referred to in the 
current literature for these compounds, we decided to perform a more thorough 
exploration of the biosynthetic options.  Herein we report the results of our biosynthetic 
analysis, which suggests that flavonolignans could be derivative through initial single-
electron oxidation of coniferyl alcohol, coupling to taxifolin, and finally an additional 
oxidation to yield silybinin and isosilybinin. 
2.2 Results and Discussion  
2.2.1. Mechanistic possibilities for biomimetic synthesis 
The conversion of coniferyl alcohol and taxifolin to silybinin and isosilybinin 
necessarily requires an oxidation.  The oxidant for this conversion is an enzyme in the 
natural environment but it has been shown that silver salts can also efficiently effect this 
conversion.  Since silver oxidations typically occur through a series of single electron 
transfers, the various mechanistic options were explored (Scheme 2.4).  In order to 
resolve the different mechanistic options, the various logical processes were explored.  
Specifically, the process necessarily involves three steps: two single electron oxidations 
and the coupling of taxifolin to coniferyl alcohol (or an oxidized variant of either 
partner). The five options discussed below cover all of the logical sequences of these 
three reactions. 
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As mentioned earlier, the prominent proposal in the literature involves 
simultaneous oxidation of both coniferyl alcohol and taxifolin and then combination of 
the resultant radicals to form ether 14 (scheme 2.4) which undergoes rapid addition of the 
phenol to the electrophilic p-quinone methide to yield silybin A (Option 1; Scheme 2.4). 
The same mechanism with opposite stereoselectivity to create ether 14 results in the 
formation of silybin B and the analogous reactions where the phenoxide radical of 
taxifolin is formed would produce the isosilybinin diastereomers. Although this 
mechanism is commonly invoked in the literature, there was no evidence to support it and 
is counter to the first principles discussed earlier. 
Option 2 involves two sequential oxidations of taxifolin to yield an o-quinone 
(12).  This option seemed much more possible since it is highly precidented to react an o-
quinone with an alkene in a Diels-Alder reaction.135  Additionally, the Diels-Alder 
reaction conserves the stereochemistry of the dienophile, so the trans-stereochemistry at 
C7'' and C8'' could result from this concerted cycloaddition. 
Options 3 and 4 are similar since they both involve single oxidation of either 
taxifolin (Option 3) or coniferyl alcohol (Option 4) and then coupling to coniferyl alcohol 
or taxifolin, respectively. The resultant radicals are further oxidized to yield silybin A.  
These two options seem possible since both coniferyl alcohol and taxifolin are electron-
rich and likely susceptible to oxidation or reaction with a radical. 
The final option explored involves two sequential oxidations of coniferyl alcohol 
and subsequent coupling to taxifolin (Option 5). It is expected that the oxidation reactions 
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occur to yield coniferyl aldehyde (16), however, it is unlikely that the redox reaction of 
this aldehyde and taxifolin would occur to yield silibin A. For the sake of this study, all 5 
of these mechanistic options were considered options while interrogating the mechanism 
via judicious choices of reaction conditions. 
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Scheme 2.4 Mechanistic Options for the Biosynthesis of Flavonolignans.
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2.2.2. Biomimetic synthesis and optimization 
The biomimetic synthesis started with natural taxifolin and commercially 
available coniferyl alcohol. Taxifolin was isolated from milk thistle extract in >90% 
purity (see experimental section). Since the starting material is relatively expensive and 
taxifolin isolated in several purification steps, reactions were initially explored on small 
scale (~1 mg taxifolin) and monitored by HPLC. The reaction conditions were based 
upon a procedure described by Merlini et al.,131 with moderate optimizations.  Several 
solvents, oxidizing agents and temperature were tested and the best results were obtained 
when reacting 1 equivalent of taxifolin with 2 equivalents of coniferyl alcohol in ethyl 
acetate containing 4 equivalents of Ag2O at 75 °C for 96 hours. These conditions 
afforded a mixture of silybin A, silybin B, isosilybin A, and silybin B in 49% yields. The 
biomimetic synthesis enhanced the yield of flavonolignans, particularly of the highly 
potent compound, isosilybin B (Scheme 2.4, Fig. 2.2, and 2.3).  
Flavonolignans 1-4 were separated by HPLC in greater than 99% purity, and their 
structures were confirmed by NMR (see experimental for more details).  In addition to 
these four flavonolignans, coniferyl aldehyde and neolignin 18 were produced in 
moderate amounts (Scheme 2.5, Fig.2.3). It is worth noting that trace amounts of 
flavonolignans 5-7 appear to be forming during some of the reactions, but the quantities 
were never sufficient to verifiably confirm their formation. 
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Figure 2.2. UPLC Chromatograms of Biomimetic Flavonolignans Compared with 
Natural Flavonolignans  
Compounds were silybin A (1) & (1′); silybin B (2) & (2′); isosilybin A (3) & (3′); 
isosilybin B (4) & (4′).  
Method: gradient of 5:95 to 80:20 over 10 min, CH3OH:H2O (HSST3 column) at 288 
nm. 
 
 
 
 
B)biomimetic flavonolignans
A) natural flavonolignans
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Scheme 2.5. Biomimetic Synthesis of Silybinin and Isosilybinin and Other Byproducts. 
 
 
 
Figure 2.3. UPLC trace of Biomimetic Reaction. 
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2.2.3. Mechanistic investigation reactions 
The initial reaction to explore the mechanistic possibilities involved the reaction 
of cis-coniferyl alcohol with taxifolin using silver oxide.  If Option 2 (Scheme 2.4) is 
occurring, the product would maintain a cis-relationship at C7'' and C8'' since the Diels-
Alder reaction maintains the stereochemistry of the dienophile.  With all of the other 
options, the stereochemistry of the initial coniferyl alcohol can be scrambled and 
presumably a trans-relationship would be produced since this is thermodynamically 
more favorable.  Importantly, cis-coniferyl alcohol* was found to produce the identical 
products as trans-coniferyl alcohol (Scheme 2.6 ; Fig. 2.4).  It is important to note that 
the cis-coniferyl alcohol did isomerize to trans-coniferyl alcohol under the conditions of 
this reaction, however, this isomerization occurred much more slowly than the rate of 
forming silybinin and isosilybinin.  These results removed Option 2 from the list of 
possible mechanisms. 
 
 
 
 
 
 
*this compound synthesized by Dr. Maria Elena Meza-Aviña 
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Scheme 2.6. Mechanistic Investigation into the Quinone Diels-Alder Possibility 
 
 
The next key mechanistic reaction explored the oxidation abilities of coniferyl 
alcohol or taxifolin individually with silver oxide in the absence of the other compound 
(Scheme 2.7).  Interesting, coniferyl alcohol is rapidly oxidized by silver oxide whereas 
taxifolin is practically inert to those oxidation conditions (Scheme 2.7; Fig. 2.5 and 2.6).  
The lack of reactivity towards oxidation of taxifolin implies that Options 1-3 in Scheme 
2.4 are all not viable mechanisms and simplifies the possibilities to only Option 4 or 5.  
Importantly, further scrutiny of the oxidation of coniferyl alcohol in the absence of 
taxifolin revealed two major products were formed, coniferyl aldehyde and neolignan 18 
(Fig. 2.5). This verifies that two oxidations of coniferyl alcohol does yield coniferyl 
aldehyde, and also that the initial radical from single-electron oxidation is prone to 
reaction with an electron-rich phenol of a different molecule of coniferyl alcohol.  
Hypothetically, if taxifolin were in solution with this singly oxidized radical, it could 
similarly react to give silybinin and isosilybinin.  Thus, the experiments by separate 
oxidations show that Options 1-3 and invalid, and that Options 4 or 5 are potential 
pathways. 
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Scheme 2.7. Individual Oxidations of Taxifolin and Coniferyl Alcohol 
 
 
As mentioned earlier, it did not seem likely that coniferyl aldehyde (16) would react with 
taxifolin to undergo a redox reaction and yield silybinin and isosilybinin.  To test this, we 
simply examined the reaction of coniferyl aldehyde with taxifolin in the both presence 
and absence of silver oxide (Scheme 2.8; Fig. 2.7).  As anticipated, silybinin and 
isosilybinin were not observed to be produced with this reaction.  Thus, the only 
remaining mechanism is Option 4 where coniferyl alcohol is oxidized, taxifolin reacts 
with the radical, and then the compound is oxidized further to yield silybinin. 
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Scheme 2.8. Attempted Coupling of Coniferyl Aldehyde to Taxifolin 
 
 
Our investigations in this area showed that none of the first three options were viable 
since taxifolin was not readily oxidized. Experiments showed consumption of coniferyl 
alcohol and formation of both coniferyl aldehyde and lignin 18 in the absence of 
taxifolin. Finally, we determined that coniferyl aldehyde and taxifolin do not react 
together in an isohypsic reaction to yield flavonolignans.  Thus, all of the experiments 
perform only support the oxidation of coniferyl alcohol to generate an intermediate 
radical of coniferyl alcohol which combines with taxifolin and is subsequently oxidized 
to silybinin and isosilybinin (Scheme 2.9). 
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Scheme 2.9. Mechanistically Supported Biosynthesis of Flavonolignans 
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A) Cis-coniferyl 
 
 
B) Reaction of Cis -coniferyl alcohol (2 equiv) with taxifolin  (1 equiv) and Ag2O (4 
equiv). 
 
Figure 2.4. UPLC chromatograms of biomimetic reaction of Cis-coniferyl alcohol with 
taxifolin. 
Method: gradient of 5:95 to 50:50 over 12 min, CH3OH:H2O (0.1% formic acid) 
(HSST3 column) at 288 nm.  Reactions were in ethyl acetate ran for 96 h at 75 °C. 
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A) Trans-coniferyl 
 
 
B) Oxidation reaction of Trans -coniferyl alcohol (2 equ) with Ag2O (4 equ). 
 
 
Figure 2.5. UPLC chromatograms of oxidation reaction of trans-coniferyl alcohol in 
absent of taxifolin. 
Method: gradient of 5:95 to 50:50 over 12 min, CH3OH:H2O (0.1% formic acid) 
(HSST3 column) at 288 nm.  Reactions were is ethyl acetate ran for 96 h at 75 °C. 
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A) Taxifolin 
 
 
 
B) Oxidation reaction of taxifolin (1 equiv) with Ag2O (4 equiv). 
 
Figure 2.6. UPLC chromatograms of oxidation reaction of taxifolin in absence of 
coniferyl alcohol. 
Method: gradient of 5:95 to 50:50 over 12 min, CH3OH:H2O (0.1% formic acid) 
(HSST3 column) at 288 nm.  Reactions were in ethyl acetate ran for 96 h at 75 °C. 
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A) Coniferyl aldehyde 
 
 
B) Oxidation reaction of coniferyl aldehyde (2 equiv) with taxifolin (1 equiv) and Ag2O 
(4 equiv). 
 
 
Figure 2.7. UPLC chromatograms of biomimetic reaction of coniferyl aldehyde with 
taxifolin. 
Method: gradient of 5:95 to 50:50 over 12 min, CH3OH:H2O (0.1% formic acid) 
(HSST3 column) at 288 nm.  Reactions were in ethyl acetate ran for 96 h at 75 °C. 
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2.3. Conclusion  
In summary, a biomimetic synthesis of four major flavonolignans present in 
silymarin is reported, accomplished in one step, and careful analysis of the reactions and 
resulting products were used to support or refute possible mechanisms.  From this 
analysis it is proposed that the biomimetic synthesis of flavonolignans likely proceeds by 
single electron oxidation of coniferyl alcohol, addition of taxifolin, and finally oxidation 
to yield silybinin and isosilybinin. This synthesis increases the yield of the most potent 
and biologically active of the flavonolignans, isosilybin B, and future studies will use this 
method to produce and study the activity of analogues of flavonolignans. 
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2.4. Experimental  
2.4.1. Taxifolin purification 
Taxifolin was isolated in >90% purity from milk thistle extract (silymarin) as 
described in fig 2.7). To purify taxifolin, two different reverse-phase columns [ODS-A 
C18 (5 µm; 250 × 20 mm) and PFP (5 µm; 250 × 21 mm)] were examined. taxifolin was 
purified until >90% pure, as measured by analytical UPLC.  First method was 15:85 to 
50:50 CH3OH:H2O (0.1 % formic acid) over 60 min using C18. Second method was 
using a gradient of 5:90 to 70:30 CH3CN:H2O (0.1% formic acid) over 30 min.  
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Method 1: Gradient of 15:85 to 50:50 over 60 min CH3OH:H2O (YMC C-18 column). 
 
 
Method 2: Gradient of 5:90 to 70:30 over 30 min CH3CN:H2O min PentaFlurophenyl 
Propyl (PFP) column. 
 
Figure 2.8. HPLC chromatograms of taxifolin separation at 288 nm.  
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2.4.2. Chemistry and Syntheses 
To a 100 ml round-bottom flask, were dissolved taxifolin (105.9 mg, 0.348 mmol) and E-
coniferyl alcohol (125 mg, 0.696 mmol) in ethyl acetate (30 mL, 0.01 M) under an 
atmosphere of nitrogen gas. After stirring for 10 min, Ag2O (323 mg, 1.39 mmol) was 
added and the flask was covered with foil and equipped with a reflux condenser.  The 
solution was stirred and heated to 75 °C for 96 h under an atmosphere of nitrogen gas. 
The reaction mixture was then cooled to room temperature and filtered through celite 
(Celite®545, 45µ) meshand washed with ethyl acetate. A yellow filtrate was 
concentrated under reduced pressure, dissolved in 2-3 ml ethyl acetate and centrifuged 
through a polypropylene eppendorf  tube filter (0.22 µm), to remove any residues of 
Ag2O.   The crude product (225 mg) was purified by reverse-phase HPLC to afford 
flavonolignans with a total yield of 82.6 mg, (21.4 mg: 21.1 mg: 20.7 mg: 19.5 mg for 1′, 
2′, 3′, and 4′, respectively), 52% of flavonolignans. In addition to the four major 
compounds, coniferyl aldehyde (16, 2.3 mg) and lignan 18 (13.6 mg) were isolated.   
The reaction mixture was first purified via a gradient of 20:80 to 50:50 
CH3OH:H2O over 90 min and hold for 20 min using YMC C18 (5 µm; 250 × 20 mm) 
column. The fractions with mixtures of isomers from the first purification were purified 
via other several rounds of a gradient of 20:80 to 50:50 over 50 min and hold for 40 min 
using YMC C18. The last purification step was by PFP column via a gradient of 20:80 to 
40:60 CH3CN:H2O (0.1 % formic acid) over 30 min. (Fig. 2.8-2.11). 
 
136 
 
Method 1 PREP-HPLC of crude biomimetic reaction mixtures: gradient of 20:80 to 
50:50 over 90 min, hold 50:50/ 70 min CH3OH: H2O (C18 column) at 288 nm. 
 
 
Method 2 Semi-PREP -HPLC of biomimetic silybin A and silybin B: gradient of 20:80 
to 50:50 50 min, hold 50:50 over 40 min CH3OH:H2O (C18 column) at 288 nm. 
 
 
Method 3 PREP-HPLC using pentafluorophenyl propyl (PFP) column: Biomimetic 
silybin B was purified using a gradient of 20:80 to 40:60 over 30 min, CH3CN:H2O 
(0.1% formic acid) at 288 nm. Biomimetic isosilybin B was purified using a gradient of 
20:80 to 60:40 over 45 min, CH3CN:H2O (0.1% formic acid) at 288 nm. 
 
 
Figure 2.9. HPLC chromatograms example of biomimetic disteroisomers separation at 
288 nm. 
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Figure 2.10. HPLC chromatograms of crude reaction mixtures (a) and co-injection of 
natural flavonolignans (b) silybin A (1); (c) silybin B (2); (d) isosilybin A (3); (e)  
isosilybin B (4) at 288 nm.  
Method: gradient of 5:95 to 80:20 over 10 min, CH3OH:H2O (HSST3 column).  
a 
b 
c 
d 
e 
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Figure 2.11. UPLC chromatograms of biomimetic flavonolignans. 
Method: gradient of 5:95 to 80:20 over 10 min, CH3OH:H2O (HSST3 column) at 288 
nm. 
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Figure 2.12. UPLC chromatograms of co-injection of biomimetic and natural 
flavonolignans. 
Method: gradient of 5:95 to 80:20 over 10 min, CH3OH:H2O (HSST3 column) at 288 
nm. 
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2.4.2.1. 4-(3-Hydroxy-prop-1-ynyl)-2-methoxy-phenol  
 
 
 
Figure 2.13. 4-(3-Hydroxy-prop-1-ynyl)-2-methoxyphenol. 
 
 
To a dry flask with a stir bar were added 4-bromo-2-methoxy-phenol (1.00 g, 4.93 
mmol), CuI (282 mg, 0.1479 mmol, 3 mol %), bis(triphenylphosphine)palladium(II) 
dichloride (104 mg, 0.1479 mmol, 3 mol %) and triethyl amine (10 ml).  The flask was 
purged with nitrogen gas and propargyl alcohol was added with stirring.  The reaction 
was heated to 95 °C for 4 hr, cooled to room temperature, filtered through celite, and 
concentrated under reduced pressure.  The crude extract was purified by silica gel column 
chromatography (85:15, hexanes:ethyl acetate) to yield 80 mg of 4-(3-hydroxyprop-1-
ynyl)-2-methoxyphenol (9 % yield) as a clear, colorless oil. 
 1H NMR (500 MHz, CDCl3) δ = 3.89 (s, 3H), 4.48 (s, 2H), 5.74 (s, 1H), 6.86 (d, J = 8.1 
Hz, 1H), 6.95 (d, J = 1.5 Hz, 1H), 7.0 ppm (dd, J = 8.1, 1.7 Hz, 1H) (see, Fig. 2.14)..  
13C NMR (125 MHz, CDCl3) δ = 51.9, 56.1, 85.5, 86.1, 114.1, 114.2, 114.7, 125.8, 
146.3, and 146.6 (see, Fig. 2.15). 
HRMS (APCI) m/z 179.06982 [M+H]+ (calcd for C10H11O3 179.07137).  
 
*: Compound synthesized by Dr. Maria Elena Meza-Aviña, 
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Figure 2.14. 1H NMR spectra of 4-(3-hydroxyprop-1-ynyl)-2-methoxyphenol 
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Figure 2.15. 13C NMR spectra of 4-(3-hydroxyprop-1-ynyl)-2-methoxyphenol 
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2.4.2.2. 4-(3-Hydroxy-propenyl)-2-methoxy-phenol or (Z)-coniferyl alcohol (19)*  
 
 
 
Figure 2.16. (Z)-coniferyl alcohol (19)  
 
 
Lindlar’s catalyst (0.016 g, 37 mol %) was added to a flask with  4-(3-Hydroxy-
prop-1-ynyl)-2-methoxy-phenol (72 mg, 0.402 mmol) in 10 ml of methanol. The reaction 
mixture was stirred for 1 hr, filtered through celite, concentrated under reduced pressure, 
and purified by silica gel column chromatography (80:20 hexanes/ethyl acetate) to yield 
37 mg of cis-coniferyl alcohol (51% yield) as a clear, colorless oil. The 1H NMR 
spectrum matched the previously reported data136 (Fig. 2.17). 
*: Compound synthesized by Dr. Maria Elena Meza-Aviña, 
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Figure 2.17. 1H NMR spectra (500 MHz) of cis-coniferyl alcohol (19) standard and isolated from reaction in DMSO-d6 . 
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2.4.2.3. Biomimetic silybin A (1′)  
 
 
 
Figure 2.18. Biomimetic silybin A (1′) 
 
 
Yield: 18 mg, 11%; white solid. 
 
 
 	 = + 19 (c 0.07, MeOH);   
UV (MeOH) max (log ) =  212 nm (4.3), 288 nm (4.1);  
CD (MeOH) ext () = 236 (+10.1) 295 (-33.7), 330 (-7.6), Fig. 2.42. 
1H  NMR (500 MHz, DMSO-d6 at 30 °C)   δ = 3.32 (m, 1H, H-9''b), 3.53 (ddd,  J = 10.3, 
5.2, 2.3 Hz, 1H, H-9''a), 3.77 (s, 3H, 3''-OCH3), 4.17 (ddd, J = 8.0, 4.6, 2.3 Hz, 1H, H-8''), 
4.60 (dd, J = 11.5, 6.3 Hz, 1H, 3-H), 4.90 (d, J = 8.0 Hz, 1H, H-7''), 4.96 (dd, J = 5.7, 5.2 
Hz, OH-9''), 5.07 (d, J = 11.5 Hz, 1H, 2-H), 5.81 (d, J = 6.3 Hz, 3-OH), 6.86 (d, J = 1.7 
Hz, 1H, H-8), 6.90 (d, J = 1.7 Hz, 1H, H-6), 6.80 (d, J = 8.0 Hz, 1H, H-5''), 6.85 (dd, J = 
8.0, 1.7 Hz, 1H, H-6''), 6.97 (d, J = 8.0 Hz, 1H, H-5'),  7.00 (dd, J = 8.0, 1.7 Hz, 1H, H-
6'), 7.01 (d, J = 1.8 Hz, 1H, H-2''), 7.09 (d, J = 1.7 Hz, 1H, H-2'), 9.18 (s, 4''-OH ), 11.90 
(s, 5-OH).  (Table 2.1, Fig. 2.19);  
13C NMR (125 MHz, DMSO-d6 at 30 °C) = δ 55.7 (3′′-OCH3), 60.2 (C-9′′), 71.4 (C-3), 
75.9 (C-8′′), 78.1 (C-7′′), 82.5 (C-2), 95.2 (C-8), 96.2 (C-6), 100.2 (C-4a), 111.6 (C-2′′), 
146 
 
115.3 (C-5′′), 116.3 (C-5′), 116.6 (C-2′),  120.5 (C-6′′), 121.4 (C-6′), 127.5 (C-1′′), 130.1 
(C-1′), 143.3 (C-3′), 143.7 (C-4′), 147.0 (C-4′′), 147.6 (C-3′′), 162.5 (C-8a), 163.3 (C-5), 
167.5 (C-7), 197.6 (C-4) (Table 2.6, Fig. 2.20);  
HSQC data = H-2→C-2; H-3→C-3; H-6→C-6; H-8→C-8; H-2'→C-2'; H-5'→C-5'; H-
6'→C-6'; H-2''→C-2''; H-5''→C-5''; H-6''→C-6'';  H-7''→C-7''; H-8''→C-8''; H-9''a→C-
9''; H-9''b→C-9''; OCH3-7→C-7; OCH3-3''→C-3''  (see Fig. 2.21). 
HMBC data = see Fig. 2.22. 
HRESIMS m/z = 481.1140 [M-H]- (calcd for C25H22O10  481.1140; see Fig. 2.23). 
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Figure 2.19. 1H NMR spectra (500 MHz, 30 °C) of silybin A (1) and biomimetic silybin A (1′) in DMSO-d6 .
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Figure 2.20. 13C NMR spectra (125 MHz, 30 °C) of  silybin A (1) and biomimetic silybin A (1′) in DMSO-d6 .
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Figure 2.21. HMBC NMR spectrum (DMSO-d6, 30 °C) of biomimetic silybin A (1′).
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Figure 2.22. HMBC NMR spectrum (DMSO-d6, 30 °C) of biomimetic silybin A (1′) .
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Figure 2.23. HRESIMS m/z 481.1140 [M-H]- of silybin A (1′) .
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2.4.2.4. Biomimetic silybin B (2′)  
 
 
 
Figure 2.24. Biomimetic silybin B (2′). 
 
 
Yield: 18 mg, 11%; white solid 
 
 
 	: +6.9 (c 0.09, MeOH);   
UV (MeOH) max (log ): 211 (4.0), 288 (3.7) nm;  
CD (MeOH) ext (): 328 (+6.5), 295 (-33.4), 234 (+34.9) nm, Fig. 2.42. 
1H  NMR (500 MHz, DMSO-d6 at 30 °C):   δ = 3.31 (m, 1H, H-9''b), 3.52 (ddd,  J = 
9.7, 5.2, 2.3 Hz, 1H, H-9''a), 3.77 (s, 3H, 3''-OCH3), 4.17 (ddd, J = 8.0, 4.6, 2.3 Hz, 1H, 
H-8''), 4.59 (dd, J = 11.5, 6.3 Hz, 1H, 3-H), 4.90 (d, J = 7.5 Hz, 1H, H-7''), 4.99 (dd, J = 
5.7, 5.2 Hz, OH-9''), 5.06 (d, J = 11.5 Hz, 1H, 2-H), 5.80 (d, J = 6.3 Hz, 3-OH), 6.82 (d, J 
= 1.7 Hz, 1H, H-8), 6.86 (d, J = 1.7 Hz, 1H, H-6), 6.80 (d, J = 8.0 Hz, 1H, H-5''), 6.86 
(dd, J = 8.0, 1.7 Hz, 1H, H-6''), 6.97 (d, J = 8.6 Hz, 1H, H-5'),  7.01 (dd, J = 8.0, 1.7 Hz, 
1H, H-6'), 7.02 (d, J = 1.7 Hz, 1H, H-2''), 7.07 (d, J = 1.7 Hz, 1H, H-2'), 9.19 (s, 4''-OH ), 
11.90 (s, 5-OH). (Table 2.1, Fig. 2.25);  
13C NMR (125 MHz, DMSO-d6 at 30 °C): δ 55.7 (3′′-OCH3), 60.2 (C-9′′), 71.4 (C-3),  
75.9 (C-7′′), 78.1 (C-8′′), 82.5 (C-2), 95.2 (C-8), 96.2 (C-6), 100.2 (C-4a), 111.6 (C-2′′),  
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115.3 (C-5′′), 116.4 (C-5′), 116.7 (C-2′),  120.5 (C-6′′), 121.2 (C-6′), 127.5 (C-1′′), 130.2 
(C-1′), 143.3 (C-3′), 143.6 (C-4′), 147.0 (C-4′′), 147.6 (C-3′′), 162.5 (C-8a), 163.3 (C-5), 
167.6 (C-7), 197.6 (C-4)  (Table 2.6, Fig. 2.26);  
HSQC data: H-2→C-2; H-3→C-3; H-6→C-6; H-8→C-8; H-2'→C-2'; H-5'→C-5'; H-
6'→C-6'; H-2''→C-2''; H-5''→C-5''; H-6''→C-6'';  H-7''→C-7''; H-8''→C-8''; H-9''a→C-
9''; H-9''b→C-9''; OCH3-7→C-7; OCH3-3''→C-3'' (see Fig. 2.27). 
HMBC data: see Fig. 2.28. 
HRESIMS m/z : 481.1141[M-H]- (calcd for C25H22O10  481.1140; see Fig. 2.29). 
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Figure 2.25. 1H NMR spectra (500 MHz, 30 °C) of silybin B (2) and biomimetic silybin B (2′) in DMSO-d6 .
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Figure 2.26. 13C NMR spectra (125 MHz, 30 °C) of silybin B (2) and biomimetic silybin B (2′) in DMSO-d6 .
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Figure 2.27. HMBC NMR spectrum (DMSO-d6, 30 °C) of biomimetic silybin B (2′). 
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Figure 2.28. HMBC NMR spectrum (DMSO-d6, 30 °C) of biomimetic silybin B (2′). 
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Figure 2.29. HRESIMS m/z 481.1141 [M-H]- of silybin B (2′).
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2.4.2.5.  Biomimetic isosilybin A (3′)  
 
 
 
Figure 2.30. Biomimetic isosilybin A (3′). 
 
 
Yield: 15 mg, 9%; white solid. 
 
 
 	 = +48.1 (c 0.1, MeOH);   
UV (MeOH) max (log ): 212 (4.3), 288 (4.1) nm;  
CD (MeOH) ext (): 329 (+3.2), 295 (-15.6), 232 (+1.6) nm, Fig. 2.42.  
 1H  NMR (500 MHz, DMSO-d6  at 30 °C) :  δ = 3.33 (m, 1H, H-9''b), 3.53 (ddd,  J = 
12.0, 5.2, 2.3 Hz, 1H, H-9''a), 3.77 (s, 3H, 3''-OCH3), 4.16 (ddd, J = 8.0, 4.6, 2.3 Hz, 1H, 
H-8''), 4.58 (dd, J = 10.9, 6.3 Hz, 1H, 3-H), 4.91 (d, J = 8.0 Hz, 1H, H-7''), 4.98 (dd, J = 
5.7, 5.2 Hz, OH-9''), 5.10 (d, J = 10.9 Hz, 1H, 2-H), 5.84 (d, J = 6.3 Hz, 3-OH), 5.86 (d, J 
= 1.7 Hz, 1H, H-8), 5.89 (d, J = 1.7 Hz, 1H, H-6), 6.80 (d, J = 8.6 Hz, 1H, H-5''), 6.86 
(dd, J = 8.0, 1.7 Hz, 1H, H-6''), 6.93 (d, J = 8.6 Hz, 1H, H-5'),  6.98 (dd, J = 8.6, 2.3 Hz, 
1H, H-6'), 7.00 (d, J = 1.7 Hz, 1H, H-2''), 7.09 (d, J = 2.3 Hz, 1H, H-2'), 9.19 (s, 4''-OH ), 
11.92 (s, 5-OH). (Table 2.1 , Fig. 2.31);  
13C NMR (125 MHz, DMSO-d6 at 30 °C ): δ 55.7 (3′′-OCH3), 60.2 (C-9′′), 71.5 (C-3),  
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75.9 (C-7′′), 78.0 (C-8′′), 82.5 (C-2), 95.3 (C-8), 96.2 (C-6), 100.2 (C-4a), 111.7(C-2′′), 
115.3 (C-5′′), 116.5 (C-5′), 116.5 (C-2′),  120.5 (C-6′′), 120.9 (C-6′), 127.5 (C-1′′), 130.4 
(C-1′), 142.9 (C-3′), 143.9 (C-4′), 147.0 (C-4′′), 147.6 (C-3′′), 162.5 (C-8a), 163.4 (C-5), 
167.7 (C-7), 197.5 (C-4)  (Table 2.2 , Fig. 2.32);   
HSQC data: H-2→C-2; H-3→C-3; H-6→C-6; H-8→C-8; H-2'→C-2'; H-5'→C-5'; H-
6'→C-6'; H-2''→C-2''; H-5''→C-5''; H-6''→C-6'';  H-7''→C-7''; H-8''→C-8''; H-9''a→C-
9''; H-9''b→C-9''; OCH3-7→C-7; OCH3-3''→C-3'' (see Fig. 2.33). 
HMBC data: see Fig. 2.34.  
 HRESIMS m/z :  481.1139 [M-H]- (calcd for C25H22O10  481.1140; see Fig. 2.35).  
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Figure 2.31. 1H NMR spectra (500 MHz, 30 °C) of isosilybin A (3) and biomimetic isosilybin A (3′) in DMSO-d6. 
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Figure 2.32. 13C NMR spectra (125 MHz, 30 °C) of isosilybin A (3) and biomimetic isosilybin A (3′) in DMSO-d6.
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Figure 2.33. HSQC NMR spectrum (DMSO-d6, 30 °C) of biomimetic isosilybin A (3′).
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Figure 2.34. HMBC NMR spectrum (DMSO-d6, 30 °C) of biomimetic isosilybin A (3′) .
 
165 
 
Figure 2.35. HRESIMS m/z 481.1139 [M-H]- of isosilybin A (3′) .
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2.4.2.6.  Biomimetic isosilybin B (4′)  
 
 
 
Figure 2.36. Biomimetic isosilybin B (4′). 
 
 
Yield: 14 mg, 8 %; white solid. 	 : -20.80 (c 0.1, MeOH);  
UV (MeOH) max (log ): 213 (4.1), 288 (3.9) nm;  
CD (MeOH) ext (): 328 (+3.8), 294 (-23.3), 228 (+16.1) nm (see Fig. 2.42).  
1H  NMR (500 MHz, DMSO-d6 at 30 °C): δ = 3.33 (m, 1H, H-9''b), 3.53 (ddd,  J = 
11.9, 5.2, 2.3 Hz, 1H, H-9''a), 3.77 (s, 3H, 3''-OCH3), 4.17 (ddd, J = 8.0, 4.6, 2.3 Hz, 1H, 
H-8''), 4.58 (dd, J = 10.9, 6.3 Hz, 1H, 3-H), 4.91 (d, J = 8.0 Hz, 1H, H-7''), 4.97 (dd, J = 
5.7, 5.2 Hz, OH-9''), 5.08 (d, J = 10.9 Hz, 1H, 2-H), 5.81 (d, J = 6.3 Hz, 3-OH), 5.83 (d, J 
= 2.3 Hz, 1H, H-8), 5.86 (d, J = 2.3 Hz, 1H, H-6), 6.80 (d, J = 8.0 Hz, 1H, H-5''), 6.85 
(dd, J = 8.0, 1.8 Hz, 1H, H-6''), 6.93 (d, J = 8.0 Hz, 1H, H-5'),  6.98 (dd, J = 8.0, 1.8 Hz, 
1H, H-6'), 7.00 (d, J = 1.8 Hz, 1H, H-2''), 7.10 (d, J = 1.8 Hz, 1H, H-2'), 9.19 (s, 4''-OH ), 
11.93 (s, 5-OH) (Table 2.1 , Fig. 2.37);  
13C NMR (125 MHz, DMSO-d6 at 30 °C): δ 55.7 (3′′-OCH3), 60.2 (C-9′′), 71.4 (C-3), 
75.8 (C-7′′), 78.0 (C-8′′), 82.4 (C-2), 95.3 (C-8), 96.3 (C-6), 100.1 (C-4a), 111.6 (C-2′′), 
115.3 (C-5′′), 116.5 (C-5′), 116.5 (C-2′),  120.5 (C-6′′), 120.9 (C-6′), 127.5 (C-1′′), 130.4 
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(C-1′), 142.9 (C-3′), 143.9 (C-4′), 147.0 (C-4′′), 147.6 (C-3′′), 162.4 (C-8a), 163.4 (C-5), 
167.0 (C-7), 197.2 (C-4) (Table 2.2, Fig. 2.38);  
HSQC data: H-2→C-2; H-3→C-3; H-6→C-6; H-8→C-8; H-2'→C-2'; H-5'→C-5'; H-
6'→C-6'; H-2''→C-2''; H-5''→C-5''; H-6''→C-6'';  H-7''→C-7''; H-8''→C-8''; H-9''a→C-
9''; H-9''b→C-9''; OCH3-7→C-7; OCH3-3''→C-3'' (see Fig. 2.39). 
HMBC data: correlations observed between the protons at δH 5.83 and 5.86 to C-7 (δC 
167.0) confirmed the presence of signal of C-7 in 4′; see Fig. 2.40). 
HRESIMS m/z: 481.1141 [M-H]- (calcd for C25H22O10 481.1140; see Fig. 2.41). 
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Figure 2.37. 1H NMR spectra (500 MHz, 30 °C) of isosilybin B (4) and biomimetic isosilybin B (4′) in DMSO-d6 
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Figure 2.38. 13C NMR spectra (125 MHz, 30 °C) of  isosilybin B (4) and biomimetic isosilybin B (4′) in DMSO-d6 
 
 
170 
 
Figure 2.39. HSQC NMR spectrum (DMSO-d6, 30 °C) of biomimetic isosilybin B (4′) correlations 
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Figure 2.40. HMBC NMR spectrum (DMSO-d6, 30 °C) of biomimetic isosilybin B (4′) correlations between the protons at H-
6, H-8 to C-7  
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Figure 2.41. HRESIMS m/z 481.1141 [M-H]- of isosilybin B (4′) 
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Figure 2.42 Circular Dichroism (CD) spectra of biomimetic flavonolignans 
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Table 2.1. 1H NMR data of flavonolignans and biomimetic flavonolignans in DMSO-d6 (500 MHz, 30 °C) 
 
Position 1 1′ 2 2′ 3 3′ 4 4′ 
2 5.08, d 
(11.5) 
5.07, d 
(11.5) 
5.08, d 
(11.5) 
5.06, d 
(11.5) 
5.11, d 
(10.9) 
5.10, d 
(10.9) 
5.11, d 
(11.5) 
5.08, d 
(10.9) 
3 4.63, dd 
(11.5, 6.3) 
4.60, dd 
(11.5, 6.3) 
4.61, dd 
(11.5, 6.3) 
4.59, dd 
(11.5, 6.3) 
4.60, dd 
(10.9, 6.3) 
4.58, dd 
(10.9, 6.3) 
4.61, dd 
(11.5, 5.9) 
4.58, dd 
(10.9, 6.3) 
6 5.91, d (1.7) 5.90, d (1.7) 5.91, d (2.3) 5.86, br d 
(1.7) 
5.92, d (2.3) 5.89, d (1.7) 5.92, d (2.0) 5.86, d (2.3) 
8 5.86, d (1.7) 5.86, d (1.7) 5.87, d (2.3) 5.82, br d 
(1.7) 
5.89, d (2.3) 5.86, d (1.7) 5.89, d (2.0) 5.83, d (2.3) 
2' 7.09, d (1.7) 7.09, d (1.7) 7.08, d (1.8) 7.07, d (1.7) 7.09, d (2.3) 7.09, d (2.3) 7.10, d (1.8) 7.10, d (1.8) 
5' 6.97, d (8.0) 6.97, d (8.0) 6.97, d (8.1) 6.97, d (8.6) 6.93, d (8.6) 6.93, d (8.6) 6.93, d (8.0) 6.93, d (8.0) 
6' 7.00, dd  
(8.0, 1.7) 
7.00, dd 
(8.0, 1.7) 
7.02, dd 
(8.1, 1.8) 
7.01, dd 
(8.6, 1.7) 
6.98, dd 
(8.6, 2.3) 
6.98, dd 
(8.6, 2.3) 
6.98, dd 
(8.0, 1.8) 
6.98, dd 
(8.0, 1.8) 
chemical shifts in δ, coupling constants in Hz 
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Table 2.1. 1H NMR (continued) 
 
Position 1 1′ 2 2′ 3 3′ 4 4′ 
2'' 7.01, d (1.8) 7.01, d (1.8) 7.02, d (1.7) 7.02, d (1.7) 7.00, d (1.7) 7.00, d (1.7) 7.00, d (2.3) 7.00, d (1.8) 
5'' 6.80, d (8.6) 6.80, d (8.0) 6.79, d (8.6) 6.79, d (8.0) 6.80, d (8.6) 6.80, d (8.0) 6.80, d (8.6) 6.80, d (8.0) 
6'' 6.86, dd 
(8.6, 1.8) 
6.85, dd 
(8.0, 1.7) 
6.86, dd 
(8.6, 1.7) 
6.86, dd 
(8.0, 1.7) 
6.86, dd 
(8.6, 1.7) 
6.86, dd 
(8.0, 1.7) 
6.86, dd 
(8.6, 2.3) 
6.85, dd 
(8.0, 1.8) 
7'' 4.90, d (7.5) 4.90, d (8.0) 4.90, d (7.5) 4.90, d (7.5) 4.91, d (8.1) 4.91, d (8.0) 4.91, d (7.5) 4.91, d (8.0) 
8'' 4.17, ddd 
(7.5, 4.6, 
2.3) 
4.17, ddd 
(8.0, 4.6, 
2.3) 
4.16, ddd 
(7.5, 4.1, 
2.3) 
4.16, ddd 
(7.5, 4.1, 
2.3)  
4.16, ddd 
(8.1, 4.6, 
2.3) 
4.16, ddd 
(8.0, 4.6, 
2.3) 
4.17, ddd 
(7.5, 4.6, 
2.3) 
4.17, ddd 
(8.0, 4.6, 
2.3) 
9''a 3.53, ddd 
(10.3, 5.2, 
2.3) 
3.53, ddd 
(10.3, 5.2, 
2.3) 
3.53, ddd 
(9.8, 4.6, 
2.3) 
3.52, ddd 
(9.7, 5.2, 
2.3) 
3.53, ddd 
(12.0, 4.6, 
2.3) 
3.53, ddd 
(12.0, 5.2, 
2.3) 
3.54, ddd 
(11.9, 5.2, 
2.3) 
3.53, ddd 
(11.9,  5.2, 
2.3)  
9''b 3.33, m  3.32, m 3.33, m  3.31, m 3.33, m  3.33, m  3.33, m  3.33, m   
chemical shifts in δ, coupling constants in Hz 
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Table 2.1. 1H NMR (continued) 
 
Position 1 1′ 2 2′ 3 3′ 4 4′ 
3''-OCH3 3.77, s 3.77, s 3.77, s 3.77, s 3.78, s 3.77, s 3.77, s 3.77, s 
3-OH 5.83, d (6.3) 5.81, d (6.3) 5.83, d (6.3) 5.80, d (6.3) 5.83, d (6.3) 5.84, d (6.3) 5.84, d (5.9) 5.81, d (6.3) 
5-OH 11.90, s 11.90, s 11.90, s 11.90, s 11.90, s 11.92, s 11.90, s 11.93, s 
7-OH 10.86, s - 10.86, s - 10.85, s - 10.86 s - 
4''-OH 9.18, s 9.18, s 9.17, s 9.19, s 9.15, s 9.19, s 9.16, s 9.19, s 
9''-OH 4.97, dd 
(5.7, 5.2) 
4.96, dd 
(5.7, 5.2) 
4.98, dd 
(5.7, 4.6) 
4.99, dd 
(5.7, 5.2) 
4.95, dd 
(5.7, 4.6) 
4.98, dd 
(5.7, 5.2) 
4.96, dd 
(5.5, 5.0) 
4.97, dd 
(5.7, 5.2) 
chemical shifts in δ, coupling constants in Hz 
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Table 2.2. 13C NMR data of flavonolignans and biomimetic flavonolignans in DMSO-d6  (125 MHz, 30 °C) 
 
Position type 1 1′ 2 2′ 3 3′ 4 4′ 
2 CH 82.6 82.5 82.5 82.5 82.5 82.5 82. 5 82. 4 
3 CH 71.4 71.4 71.4 71.4 71.5 71.5 71.5 71.4 
4 C 197.8 197.6 197.7 197.6 197.8 197.5 197.8 197.2 
4a C 100.4 100.2 100.4 100.2 100.5 100.2 100.5 100.1 
5 C 163.3 163.3 163.3 163.3 163.3 163.4 163.3 163.4 
6 CH 96.1 96.2 96.1 96.2 96.1 96.2 96.1 96.3 
7 C 167.1 167.5 166.9 167.6 166.9 167.7 166.9 167.0  
8 CH 95.1 95.2 95.0 95.2 95.1 95.3 95.1 95.3 
8a C 162.5 162.5 162.4 162.5 162.5 162.5 162.5 162.4 
1' C 130.1 130.1 130.1 130.2 130.3 130.4 130.3 130.4 
2' CH 116.6 116.6 116.6 116.7 116.5 116.5 116.5 116.5 
3' C 143.3 143.3 143.2 143.3 142.9 142.9 142.9 142.9 
4' C 143.7 143.7 143.6 143.6 143.9 143.9 143.9 143.9 
chemical shifts in δ 
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Table 2.2. 13C NMR (continued) 
 
Position type 1 1′ 2 2′ 3 3′ 4 4′ 
5' CH 116.3 116.3 116.3 116.4 116.4 116.5 116.5 116.5 
6' CH 121.4 121.4 121.4 121.2 120.9 120.9 120.9 120.9 
1'' C 127.5 127.5 127.5 127.5 127.5 127.5 127.5 127.5 
5' CH 116.3 116.3 116.3 116.4 116.4 116.5 116.5 116.5 
6' CH 121.4 121.4 121.4 121.2 120.9 120.9 120.9 120.9 
1'' C 127.5 127.5 127.5 127.5 127.5 127.5 127.5 127.5 
2'' CH 111.6 111.6 111.6 111.6 111.7 111.7 111.7 111.6 
3'' C 147.6 147.6 147.6 147.6 147.6 147.6 147.6 147.6 
4'' C 147.0 147.0 147.0 147.0 147.0 147.0 147.0 147.0 
5'' CH 115.3 115.3 115.3 115.3 115.3 115.3 115.3 115.3 
6'' CH 120.5 120.5 120.5 120.5 120.5 120.5 120.5 120.5 
7'' CH 75.9 75.9 75.8 75.9 75.9 75.9 75.9 75.8 
chemical shifts in δ 
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Table 2.2. 13C NMR (continued) 
 
Position type 1 1′ 2 2′ 3 3′ 4 4′ 
7'' CH 75.9 75.9 75.8 75.9 75.9 75.9 75.9 75.8 
9'' CH2 60.2 60.2 60.2 60.2 60.2 60.2 60.2 60.2 
3''-OCH3 CH3 55.7 55.7 55.7 55.7 55.7 55.7 55.7 55.7 
chemical shifts in δ 
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2.4.2.7. Coniferyl aldehyde (16)  
 
 
 
 
 
 
Figure 2.43. Coniferyl aldehyde 
 
 
Yield: 2.3 mg, 2%; this compound was isolated from the biomimetic reaction and 
oxidation reaction of coniferyl alcohol. The 1H NMR data matched literature values and 
that from coniferyl aldehyde purchased from Aldrich 135 
 
1H NMR (500 MHz, acetone-d6) δ = 3.93 (s, 3H, 3-OCH3), 6.68 (dd, J = 15.6, 7.8 Hz, 
1H, H-8), 6.91 (d, J = 7.8 Hz, 1H, H-5), 7.22 (dd, J = 7.8, 1.8 Hz, 1H, H-6), 7.39 (d, J = 
15.6 Hz, 1H, H-2), 7.58 (d, J = 15.6 Hz, 1H, H-7), 9.64 (d, J = 7.8, Hz, 1H, H-9).  (Fig. 
2.44).  
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Figure 2.44. 1H NMR spectra (500 MHz) of coniferyl aldehyde (16) standard and isolated from reaction in acetone-d6 .
 
coniferyl aldehyde standard (sigma) 
coniferyl aldehyde isolated 
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2.4.2.8. Dehydrodiconiferyl Alcohol (18)  
 
 
 
Figure 2.45. Dehydrodiconiferyl Alcohol 
 
 
Yield: 13.6 mg, 6%; this lignin was isolated from the biomimetic reaction and oxidation 
reaction of coniferyl alcohol. The 1H and 13C NMR data matched literature values.136  
1H NMR (500 MHz, acetone-d6) δ = 3.53 (q, J = 6.3 Hz, 1H, H-8), 3.82 (s, 3H, 3-
OCH3), 3.83 (dd, J = 10.3, 6.9 Hz, 1H, Ha-9), 3.86 (s, 3H, 3′-OCH3), 3.88 (dd, J = 10.3, 
5.2 Hz, 1H, Hb-9), 4.20 (dd, J = 5.7, 1.8 Hz, 1H, H-9′), 5.56 (br d, J = 6.3 Hz, 1H, H-7), 
6.24 (dt, J = 16.0, 5.2 Hz, 1H, H-8′), 6.52 (dt, J = 16, 1.7 Hz, 1H, H-7′), 6.81 (d, J = 8.0 
Hz, 1H, H-5),6.88 (dd, J = 8.0, 1.7 Hz, 1H, H-6), 6.95 (d, J = 1.7 Hz, 1H, H-2′), 6.98 (br 
s, 1H, H-6′), 7.04 (d, J = 2.3 Hz, 1H, H-2) (Table 2.3, Fig. 2.46). 
13C NMR (125 MHz, acetone-d6) δ 54.8 (C-8), 56.3 (C-3-OCH3), 56.4 (C-3′-OCH3), 
63.5 (C-9′), 64.6 (C-9), 88.6 (C-7), 110.5 (C-2), 111.6 (C-2′), 115.7 (C-5), 116.1 (C-6′), 
119.6 (C-6), 128.4 (C-8′), 130.4 (C-5′), 130.5 (C-7′), 132.0 (C-1′), 134.4 (C-1), 145.2 (C-
3′), 147.4 (C-4), 148.4 (C-3), 149.0 (C-4′) (Table 2.4, Fig 2.47). 
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Figure 2.46. 1H NMR spectra (500 MHz) of dehyderodiconiferyl alcohol (18) isolated 
from reaction in acetone-d6
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Figure 2.47. 13C NMR spectra (125 MHz) of dehyderodiconiferyl alcohol (18) isolated 
from reaction in acetone-d6 
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Table 2.3. 1H NMR spectra comparison of dehyderodiconiferyl alcohol (18) with 
literature values in acetone-d6 
 
Position Type Experimental 
(shift, multiplicity, coupling) 
Literaturea
(shift, multiplicity, coupling) 
2 CH 7.04, d (2.3) 7.03, d (2.0) 
5 CH 6.81, d (8.0) 6.80, d (8.1) 
6 CH 6.88, dd (8.0, 1.7) 6.87, ddd (8.1, 2.0 and 0.5) 
7 CH 5.56, br d (6.3) 5.56, dt (6.3, not given) 
8 CH 3.53, q (6.3) 3.53 br q ( not given) 
9a CH2  3.83, dd (10.3, 6.9) 3.78 m 
9b CH2 3.88, dd (10.3, 5.2) 3.88 m 
OCH3 CH3 3.82, s 3.81, s 
 CH 6.95, d (1.7) 6.94, br s ׳2
 CH 6.98, br s 6.97, br s ׳6
 (CH 6.52, dt (16.0, 1.7) 6.52, dt (15.8, 1.5 ׳7
 (CH 6.23, dt (16.0, 5.2) 6.23, dt (15.8, 5.5 ׳8
 (CH2 4.20, dd (5.7, 1.8) 4.19, td (5.2, 1.5 ׳9
OCH3 CH3 3.86, s 3.85, s 
chemical shifts in δ, coupling constants in Hz  
aQuideau, S.; John, R. Holzforschung , 1994, 48, 12-22. 
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Table 2.4. 13C NMR data of dehyderodiconiferyl alcohol (18) with literature values in 
acetone-d6 
 
Position type Experimental  Literaturea 
1 C 134.4 134.4 
2 CH 110.5 110.5 
3 C 148.4 148.4 
4 C 147.4 147.3 
5 CH 115.7 115.7 
6 CH 119.6 119.6 
7 CH 88.6 88.5 
8 CH 54.8 54.7 
9 CH2 64.6 64.6 
OCH3 CH3 56.3 56.3 
1 C 132.0 131.9 
2 CH 111.6 111.7 
3 C 145.2 145.1 
4 C 149.0 148.8 
5 C 130.5 130.4 
6 CH 116.1  116.1  
7 CH 130.5 130.5 
chemical shifts in δ 
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Table 2.4. 13C NMR (continued) 
 
Position type Experimental  Literaturea 
8 CH 128.4 128.3 
9 CH2 63.5 63.4 
OCH3 CH3 56.4 56.4 
chemical shifts in δ  
aQuideau, S.; John, R. Holzforschung , 1994, 48, 12-22. 
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